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MYROSLAWA HAPPE. The potential mechanisms of impaired pneumococcal vaccine
responses in aging HIV-positive individuals. (Under the direction of JULIE
WESTERINK).

Abstract
The introduction of antiretroviral therapy has significantly reduced HIV-related
morbidity and mortality and transformed HIV infection into a chronic disease.
Consequently, the life expectancy of HIV-positive individuals considerably improved
leading to a rapid growth of the aging HIV-positive population. Together, advanced age
and HIV infection increase susceptibility to potentially deadly infections caused by
Streptococcus pneumoniae. Despite preventative approaches, such as pneumococcal
vaccination, it remains a challenge to induce potent and durable immune responses against
pneumococcal polysaccharides in HIV-positive persons and invasive pneumococcal
disease rates remain 35-fold higher as compared to healthy individuals. Poor responses to
vaccine antigens in HIV+ individuals are at least in part, related to intrinsic B cells defects.
Herein, we investigated the potential mechanisms of impaired vaccine responses in aging
HIV+ individuals. First, we measured quantitative and qualitative antibody responses in
young and aging HIV+ individuals as compared to age-matched HIV- controls. We found
that similarly to aging HIV- persons, both young and aging HIV+ persons have
significantly reduced antibody production and functionality as compared to young HIVindividuals. Interestingly, we found that there are profound race-related differences in
functional antibody response to pneumococcal vaccination in HIV-infected individuals
regardless of age. Next, we assessed the molecular signals that may influence diminished
responses to pneumococcal vaccination in the aging HIV+. This assessment revealed, that
there is a correlation between high levels of expression of pro-inflammatory cytokine IPxii

10 and functional antibody titers in aging HIV+ population. To further probe mechanisms
of impaired vaccine responses, we examined the phenotype, individual cellular changes
and inter-cellular gene expression that shape polysaccharide-specific B cell responses by
utilizing flow cytometry and single cell genomics approaches. We showed the phenotype
of polysaccharide specific B cells changes with age from predominantly IgM-memory
(CD27+IgM+) to switched memory (CD27+IgM-) in HIV-negative individuals. However, in
HIV+ individuals there is no age-related shift. Furthermore, aging HIV+ displayed a phenotype
similar to young HIV- individuals but in significantly reduced percentages. Single cell genomic
studies of pre-immunization and post-immunization IgM memory B cells demonstrated
significant heterogeneity and identified two distinct cellular subpopulations of IgM memory that
were found in both HIV+ and HIV- persons. A subpopulation of IgM memory B cells with high
levels of expression of CD80, BAFF-R, TACI, and TCF3 is speculated to play a dominant role
in a production of robust immune response to PPS-antigens. It was more frequently observed in
healthy young adults and in aging HIV+ individuals. However, despite higher prevalence of this
subpopulation in aging HIV+ group pre- and post-immunization, the absolute number of IgM
B cells was very low and potentially had a more significant impact on the ability to respond to
TI-2 antigens. These data suggest that both heterogeneity and low absolute number of IgM
memory B cells play an important role in impaired pneumococcal vaccine responses. In
conclusion, our study demonstrated that the immune response to pneumococcal vaccination in
aging HIV-positive individuals is influenced by multiple factors including HIV infection, age,
race, levels of inflammation, and phenotype of IgM memory B cells. Therefore, improved
understanding of intrinsic B cell defects in HIV+ population is necessary in order to identify
new potential adjuvant targets for use in future vaccine formulations.
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Chapter 1
Streptococcus pneumoniae
1.1.

Introduction
Streptococcus pneumoniae, commonly known as pneumococcus was one of the

first human pathogens to be isolated and characterized. Two scientists, Louis Pasteur and
George M. Sternberg, discovered S.pneumoniae independently in 1881 and set the stage
for ground breaking discoveries that led to our modern understanding of pneumococcal
pathogenesis, structure, and immunity.1 During the same period, between 1881 and 1887
it was established that S. pneumoniae was a causative agent of not only pneumonia but also
of a spectrum of pneumococcal infections ranging from a mild disease such as otitis media
and sinusitis to invasive forms such as meningitis and bacteremia.1

Today, the

pneumococcus continues to be a major human pathogen. It is the most common cause of
community acquired bacterial pneumonia (CAP) and a significant cause of invasive
pneumococcal disease (IPD).2 Global efforts to control the infection have led to the
discoveries of fundamental aspects of pneumococcal biology resulting in the development
of polysaccharide vaccines and an understanding of antibiotic resistance.3 However,
despite these advances, pneumococcal infections remain a significant cause of morbidity
and mortality worldwide.4,5,6,7
1.2.

Characteristics and virulence factors
S.pneumoniae is a highly-invasive, gram-positive, lancet-shaped bacterium usually

found in pairs as diplococci. S. pneumoniae is a facultative anaerobe and can survive in
both aerobic and anaerobic conditions.8 The pneumococcal outer surface contains a thick
cell wall and capsular associated polysaccharides. The cell wall of S. pneumoniae is
1

composed of peptidoglycan and a covalently attached teichoic acid. It functions to protect
and shape the cell. Capsular polysaccharides (CPSs) consist of several hundred highmolecular weight surface saccharides that vary in composition, ring form structure, isomer
forms, glyosidic linkage positions, and anomeric center configurations.9,10 The majority of
CPSs are negatively charged due to the presence of pyruvate, acidic sugars, or phosphate.
It is proposed that negative charge on CPSs facilitates pneumococcal colonization by
electrostatically repelling pneumococci from 1) negatively charged phagocytic cells and 2)
negatively charged sialic acid-rich mucopolysaccahrides found in mucus, which leads to
the reduction of clearance rates by mucociliary flow.11,12 Several CPSs, however, are not
charged (7A, 7F,14,33F,33A, and 37) and serotype 1 is zwitterionic, meaning it contains
both positive and negative charges.11,13 Based on the differences in the structure and
linkage of saccharides as well as other components of CPSs, over 90 different serotypes of
S.pneumoniae have been identified. In general, serotypes differ significantly in clearance
rates, prevalence, and in their ability to induce immune responses and cause the disease.
Despite the wide diversity of pneumococcal structures, all serotypes share a conserved
function of bacterial immunity and mechanisms of invasion.11
Polysaccharide capsule is a major virulence factor of S.pneumoniae. It is a critical
element of bacterial colonization and is used as a target for vaccine formulations. Studies
have shown that invasive cases of S.pneumoniae infection were caused only by
encapsulated serotypes and that upon genetic mutation or degradation of CPSs, the
virulence capabilities of S. pneumoniae were dramatically reduced.14 Therefore, CPSs
dictate the severity of bacterial invasion. It also functions to protect bacteria from being
recognized by the defensive mechanisms of the immune system; it prevents host opsonins,
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such as C3 and its fragments from depositing on the surfaces of the bacteria, consequently
inhibiting complement activation and phagocytosis.9,15
S.pneumoniae possesses a unique property called “phase variation”, which
promotes successful invasion of the host. Phase variation is a spontaneous change between
transparent and opaque colony phenotypes. Transparent phenotypes are characterized by
reduced capsular polysaccharide which enhances adherence to human epithelial cells, in
contrast, opaque phenotypes are characterized by a thicker capsule, making them more
resistant to opsonophagocytosis and, therefore, more invasive.16 Advances in research and
an in depth understanding of pneumococcal polysaccharides as the most significant virulent
factor has led to their incorporation into vaccine development which will be discussed later
(discussed in Chapter 1.6).
In addition to polysaccharide capsule, several proteins have also been implicated in
the virulence of S.pneumonaie. One of these proteins is pneumococcal surface protein A
(PspA). PspA is found on the surface of all pneumococcal strains.17 It is composed of three
structural domains and possesses highly electronegative properties which allow it to inhibit
complement-mediated opsonization.17,18,19 Another virulence protein is pneumococcal
surface protein C (PspC). Similarly to PspA protein, it inhibits opsonization by binding to
factor H and, thus prevents the formation of C3b of the alternative complement pathway
and averts opsonization of bacteria.20 PspA, a highly immunogenic protein, is considered
to be a promising vaccine candidate. Formulation of vaccine that is protein antigen-based
(e.g. PspA) as compared to purified capsular polysaccharide based could result in
significant increases in immunogenicity, immune memory and confer serotype-
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independent protection. Currently, this type of vaccine is being tested in clinical
trials.21,22,23
1.3.

Transmission and colonization
Pneumococcal colonization is not only prerequisite to invasive disease but also

essential for transmission which occurs primarily through direct contact with respiratory
secretions including saliva and mucus of an infected person. In healthy individuals S.
pneumonaie colonizes the mucosal surfaces of the upper respiratory tract (URT) including
nasal cavity, pharynx, and larynx.24 Typically, colonization is an asymptomatic process
distinguished by adherence of S.pneumoniae to cell surface carbohydrates on non-inflamed
epithelium of the respiratory tract, yet still stimulating the production of serotype-specific
antibodies.25,26 Under favorable conditions however, the bacterium may become
pathogenic and transform asymptomatic colonization into potentially life-threatening
disease. This process is influenced by bioactivity of pneumococcal cell wall components
that lead to activation of endothelia, epithelia, and leukocytes to secrete inflammatory
factors such as interleukin-1(IL-1) and tumor necrosis factor (TNF). As a result,
pneumococcal membrane glycoprotein enzyme called neuraminidase (NanA) cleaves Nacetylneuraminic acid from mucin causing the mucus to become less viscous and
enhancing colonization. This also triggers N-acetyl-glycosamine (GlcNac) receptors on the
epithelial cells to become exposed and initiate interaction with PsaA. 9,25 In addition, host
epithelial cells upregulate expression of platelet-activating factor receptors (PAFr), which
becomes bound to pneumococcal cell-wall phosphocholine (ChoP).27,28 This cascade
initiates internalization of pneumococci and transcellular migration through respiratory
epithelium and vascular endothelium. During the invasion, the bacteria escape endocytosis-
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mediated killing by yet to be defined mechanism and cause invasive disease.26,29
Colonization rates vary with age and the environment. The highest S. pneumoniae carriage
is found among children under the age of two (30-40%) whereas carriage in the adults is
reduced to less than 10 percent. 26
1.4.

Epidemiology and burden of pneumococcal disease
Pneumococcal infection is a significant cause of morbidity and mortality

worldwide. The incidence of invasive pneumococcal disease is influenced by age,
geographical location, comorbidities, serotype prevalence, and vaccination status. A recent
study reports that pneumococcal disease is responsible for over 4 million illnesses, 445,000
hospitalizations and 22,000 deaths annually in the United States.30 Pneumococcal disease
rates are the highest among individuals at extremes of age, children under the age of five
and the elderly. Globally, pneumococcal infection is responsible for almost a million lethal
cases in young children (under the age of five) which accounts for 11% of 6.6 million total
deaths.31 In the developed nations, however, the frequency of pneumococcal disease in
children declined substantially due to routine immunizations. The elderly population, on
the other hand, despite immunization practices and the effects of “herd immunity”, still
remains at an increased risk for pneumococcal infections. Studies have shown that
pneumococcus is the most common bacterial pathogen isolated from elderly patients with
community acquired pneumonia (CAP) and accounts for up to 30 % of all CAP cases. The
frequency of invasive pneumococcal disease (IPD) is also high among the elderly
population. Almost 36,000 cases of IPD were reported in 2011 in the USA; 54% occurred
in adults above 50 years of age.

32,33

Although age is a significant risk factor for

pneumococcal infections, other factors play a role. These include comorbidities such as
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chronic lung disease, diabetes mellitus, chronic liver disease, chronic cardiovascular
disease, renal failure and others. Ethnicity and immune deficiencies, including HIV
infection, also increase risk of pneumococcal disease.34 It is estimated that the burden of
pneumococcal disease within HIV-positive population treated with combined antiretroviral
therapy (cART) is still 35-fold higher as compared to non-infected individuals.35 The
introduction of cART has increased longevity in HIV-positive individuals resulting in a rapid
growth of aging HIV+ population. In 2015, it was estimated that almost 50% of Americans
living with HIV were aged 50 and older, and 16% of these were aged 65 and older.
Furthermore, among new HIV diagnoses in 2016 in the United States, people aged 50 and
older accounted for 17%.36 The increasing lifespan of HIV+ persons represent new challenges
combining the immune deficiencies of HIV with those of age and consequently enhance
susceptibility to pneumococcal infections. Together, these statistics clearly demonstrate the
need for continued efforts to control and prevent pneumococcal disease worldwide.
1.5.

Therapeutic interventions
Current strategies to treat pneumococcal infections utilize either monotherapy or a

combination therapy of antibiotics. Until the early 1970s, the majority of pneumococcal
infections were easily treated with the most common antibiotics including penicillins,
clindamycin, macrolides, rifampin, vancomycin, and trimethoprim-sulfamethoxazole.
However, in the beginning of 1990s, a large portion of pneumococcal isolates began
demonstrating resistance to the accepted antibiotic treatment protocols. Later, in 2007,
drug-resistant S.pneumoniae isolates have become increasingly common not only in the
United States, but worldwide.37,38 In 2015, there were 30,000 cases of documented invasive
pneumococcal disease and 30% of these were resistant to one or more antibiotics.39
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According to the Center for Disease Control (CDC), antibiotic resistance results in almost
1.2 million illnesses and over 7,000 deaths per year. The majority of cases and deaths occur
among adults 50 years or older, with the highest rates among individuals 65 or older.37
Therefore, prophylaxis and achievement of high vaccination coverage is important in order
to control the spread of pneumococcal resistance.
1.6.

Pneumococcal vaccines
The first attempts in formulating pneumococcal vaccines date back to 1891, when

Georg Klemperer and his brother Felix Klemperer demonstrated that the injection of heatinactivated pneumococci conferred serotype-specific immunity to re-infection in rabbits.
These findings laid a foundation for serum therapy which was used on the empirical basis
up until 1940s. Meanwhile, in early 1900’s Sir Almroth E. Wright conducted a number
of trials of whole-cell pneumococcal vaccine in a group of gold miners in South Africa.
This vaccine was formulated from circulating strains without the regard to serotype
specificity. The results of the trials, demonstrated that the whole-cell vaccine was able to
provide a degree protection and lead to reduction of pneumonia cases and death
incidences among South African gold miners. It was not until 1914, when Sir F. Spencer
Lister developed a typing system, which allowed the design of the first serotype-specific
whole-cell pneumococcal vaccine containing three serotypes (1, 2, and serotype 5); later
this vaccine was expanded to eight serotypes. According to modern epidemiological
methods, the vaccine efficacy was close to 34% in preventing pneumonia and 42% in
reducing mortality rates among six different studies done in patients with influenza.40
In 1917, the first capsular polysaccharide was isolated, and in 1930s it was shown that pure
pneumococcal polysaccharides were able to induce antibody production in humans. Based
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on these findings, the first bivalent pneumococcal vaccine was developed against serotypes
1 and 2.40,41 In the 1970s, a large clinical trial was conducted on South African gold miners
using experimental 6- and 12-valent pneumococcal polysaccharide vaccines (PPV).
Among the miners, there was a 76% reduction in pneumococcal pneumonia cases for the
6-valent vaccine and up to 92% for 12-valent vaccine.42 These findings clearly illustrated
advantages of PPV and lead to the development and licensing of the 14-valent
pneumococcal polysaccharide vaccine (PPV14) in 1977 for adults 50 years and older and
children 2 years old and older with certain underlying conditions. The serotypes included
in the vaccine were targeting up to 70% of IPD causing serotypes at the time.40 In 1983,
due to global needs of larger serotype coverage, PPV23 (Pneumovax23) a new and
improved version of pneumococcal polysaccharide vaccine was developed. PPV23 is
presently used and contains 23 serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F,
14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F, has improved safety and
immunogenicity, and covers more than 85% of the organisms that cause IPD 43. Studies
have shown that PPV23 is highly effective against IPD in young, healthy adults32. In
contrast, PPV23 was found to be ineffective in children under the age of two.44
Furthermore, PPV23 showed only suboptimal protection in the elderly and in
immunocompromised HIV+ population. A recent meta-analysis study of 7 trials, with more
than 100,000 participants, found that PPV23 can provide a significant protective effect
against all-cause pneumonia but not against other clinical outcomes in immunocompetent
adults, especially in high risk populations including the elderly. PPV23 showed promising
effects on preventing CAP with up to 87% rate reduction.45Another meta-analysis study by
H.Latifi-Navid et al came to similar conclusions.46 In HIV+ individuals PPV23 was only

8

50% effective in preventing IPD.47 Although, PPV23 showed protection against most
invasive forms of pneumococcal disease, it could not prevent other forms of pneumococcal
infections, nor could it induce immune response in infants.44,48,49
The shortcoming of PPV23 led to the development of the third-generation of
pneumococcal vaccines which contain PPS conjugated to a protein carrier. Unlike PPV23
that stimulates T cell independent immune responses, the new pneumococcal conjugate
vaccine (PCV) stimulates T cell dependent immune response due to covalent coupling of
PPS to an immunogenic carrier protein such as non-toxic mutant of diphtheria toxin
(CRM-197). Conjugation of polysaccharides is a complex process; therefore, the serotype
coverage is limited. The first PCV vaccine (PCV7) included capsular PSs of seven
serotypes: 4, 6B, 9V, 14, 18C, 19F, and 23F was licensed in 2000 in the United States for
use in infants and young children.32,40 PCV7 proved to be highly effective in preventing
IPD in children and had a significant impact on otitis media.44Interestingly, routine infant
PCV7 immunization had reduced transmission of PCV7 serotypes, resulting in reduction
of vaccine type IPD in unvaccinated adults, a phenomenon called “herd immunity”.
According to CDC, the rates of IPD decreased by 34% in persons aged 18-49, 14% in
persons aged 50-64, and 37% in persons over the age of 65 from 1998 to 2009.50
However, the observed benefits of PCV7 became limited, when a shift in serotype
prevalence occurred leading to an increase in infections due to non-vaccine serotypes.
Most prominent was serotype 19A, which quickly developed high prevalence of multidrug resistance in the clinical setting. This encouraged the development and licensure of
the currently available 13-valent conjugate vaccine (PCV13, Prevnar13) in the USA in
2010. PCV13 contains six additional serotypes (1, 3, 5, 6A, 7F, and 19A). PCV13 has
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added a significant benefit over PCV7 and resulted in the reduction of vaccine-type IPD
in vaccinated and unvaccinated individuals. 51
The success demonstrated by PCV13 vaccine in young children prompted its
consideration for use in adults. In 2012, the Food and Drug Administration (FDA)
approved the use of PCV13 in adults over the age of 50 as well as in immunocompromised
individuals. A recent, double-blind, placebo-controlled trial in the Netherlands involving
almost 85,000 study participants 65 years of age or older showed PCV13 to be 75%
effective in protecting from IPD and 45.6% effective in preventing CAP. When they
looked at vaccine serotype reduction, the efficacy was only 31% as previously seen with
PPV23. However, limitations of this study include lack of comparison between the
effectiveness of PCV13 and PPV23 and also the fact that the study was performed among
a very homogenous population.52 PCV13 was also found to be effective in HIV+
population. M. Glesby et al in a small-scale study showed that in HIV-infected subjects
who previously received a single dose of PPV23 and had CD4 counts above 200 cell/mm3
with suppressed viral loads, vaccination with PCV13 induced functional antibody
response against certain serotypes.53 However, when these results were compared to
antibody response in PPV23 naïve healthy adults over the age of 50, antibody titers in
HIV+ were still lower.53 Together, these findings demonstrate current limitations of
vaccine efficacy in high risk populations and shortage of serotype coverage emphasizing
the need of development of new vaccination strategies.
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1.6.1. Mechanism of immune response to pneumococcal vaccines: immunogenicity
and vaccine efficacy
In contrast to protein antigens, capsular polysaccharides are T cell independent
antigens type 2 (TI-2) that stimulate humoral antibody response without T cell help. 54,55
Nevertheless, T cell derived cytokines such as interleukin-2 (IL-2), IL-5, IL-10, and
interferon-gamma (IFN-γ) play a role in TI-2 immune responses.56 CPSs antigens contain
multiple identical antigenic epitopes, which activate B cells by cross-linking the antigen
specific B-cell receptors (BCR) and driving the production of high avidity antigen specific
antibodies. CPSs do not induce the production of immunological memory, instead memory
B cells are terminally differentiated into plasma cells. As a result, there is a depletion of
memory B cell pool, which leads to immune tolerance or hyporesponsiveness to future
vaccinations.57 Therefore, immunization with PPV23, which contains purified PPS,
generates anti-capsular antibodies through TI-2 mechanisms with limitation to the B cell
responses.
In contrast, the mechanism of immune response induced by PCV13 vaccine is T
cell dependent (TD). Chemical conjugation of PPS to a protein directs processing of the
protein carrier by polysaccharide specific B cells. Processed peptide is presented by major
histocompatibility complex II (MHC II) to carrier-peptide-specific CD4+ T cells leading
to induction of T cell-dependent (TD) immune response even in infants. Furthermore, T
cell dependent response to PCV13 can produce long term immunological memory through
the production of new memory B cells.57
The main subset of B cells that responds to PPS antigens is a topic of debate. Studies
suggest that marginal zone (MZ) B cells are involved in polysaccharide-specific immune
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response. MZ B cells are located in the spleen, a lymphoid organ that functions as a bridge
between the circulation and the immune system, and can recirculate between blood and
splenic marginal zone in humans.58 MZ B cells, express polyreactive B cell receptors
(BCR) which allows them to bind to various microbial molecular patterns and rapidly
respond to antigens.59 TI-2 antigens enter MZ through the perifollicular zone, a
compartment of the spleen between the MZ and the red pulp. Antigen capture involves
neutrophil extracellular trap (NET)-like structures and secretion of interleukin-10 (IL-10)
by perifollicular sinus-lining cells and macrophages in response to microbial Toll-like
receptor (TLR) ligands.60,61 Furthermore, antigen capture leads to the release of B cell
activating factor (BAFF) and a proliferation-inducing ligand (APRIL) and engagement of
transmembrane activator and CAML interactor (TACI) on MZ B cells which induces B
cell survival, somatic hypermutation, class-switch recombination and antibody production
in MZ B cells.60
BAFF and APRIL are members of tumor necrosis factor receptor family (TNFR)
and together with their ligands are instrumental in humoral immune response to TD and
TI-2 antigens.62 Pathogens induce expression of BAFF and APRIL by antigen capturing
cells such as macrophages and dendritic cells through the engagement of pattern
recognition receptors by pathogen associated molecular patterns. Expression of type I and
type II IFNs also leads to the induction of BAFF and APRIL, activation of B cells and
production of pathogen-specific antibodies.60,63 Ligand-receptor interaction within BAFFAPRIL are both redundant and specific. BAFF is required for B cell homeostasis, however
overexpression of BAFF leads to increase in autoantibody production and manifestation of
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autoimmune conditions. Unlike BAFF, APRIL deficiency does not cause severe
abnormalities.63,64
BAFF binds to three different receptors of the TNF receptor family: B-cell
maturation antigen BCMA (CD269), TACI (CD267), and BAFF-receptor, BAFF-R, (BR3
or CD268). BCMA (B cell maturation antigen) is preferentially expressed on mature
antibody producing B lymphocytes and plays a role in B cell development, plasma cell
survival, and autoimmune responses. In BCMA deficient mice humoral immune responses
to TI-2 and TD antigens are normal, but endurance of long-lived plasma secreting cells is
impaired.65,66 TACI is predominantly expressed on MZ B cells and plays a role in humoral
immunity by controlling TI antibody response and isotype switching.63,67 TACI
engagement by BAFF or APRIL leads to an increase in activation-induced cytidine
deaminase (AID) transcription levels consequently causing polysaccharide specific
antibody switch to IgA and IgG and generation of plasma cells. TACI is also a positive
regulator of B cell growth and CD40-independent antibody (Ab) production.68 Studies have
shown that TACI deficient mice develop intemperate number of B cells, are unable to
produce TI responses and fail to develop IgM and IgG after challenge with TI-2
antigens.69,70 In humans, expression of TACI is enhanced on polysaccharide specific B
cells, highlighting its potential role in PPV23 response.71 BAFF-R is strictly expressed on
B cells and regulates peripheral B cell population and isotype switching. It has been shown
that signaling through BAFF-BAFF-R system is absolutely required for the formation of
mature B cell compartment.72,73 BAFF-R expression is absent on B cell precursors in the
bone marrow, but it is gained on immature B cells once they acquire a BCR. Studies have
shown that BAFF-R deficient mice have impaired development of marginal zone B cells
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and follicular B cells.73,74 BAFF-R deficiency in humans is characterized by a low number
of circulating B cells and low concentrations of IgM and IgG in the serum.75 BAFF binds
strongly to BAFF-R and TACI, but weakly to BCMA, interestingly APRIL binds weakly
to TACI and strongly to BCMA and does not bind to BAFF-R.76 Taken together, there is
strong evidence that TACI and BAFF-R are critical in humoral immune responses to TI-2
antigens in humans and grants their exploration in understanding how they regulate
immune response to pneumococcal vaccination.
Another critical component in response to TI-2 antigens such S. pneumoniae PPSs
is interleukin-21 (IL-21), which induces class-switching recombination, somatic
hypermutations, and antibody production in MZ B cells. Rapid B cell differentiation into
IgM secreting cells or class-switched IgG secreting cells is accompanied by production of
IL-6, IL-10, and CXC-chemokine ligand 10 (CXCL10) by antigen capturing cells.60
Maturation of the splenic marginal zone and ability to respond to TI-2 antigens
occur later in life, therefore infants cannot respond to polysaccharide antigens including
the ones present in PPV23 vaccine. Individuals with congenital asplenia or lacking the
spleen due to surgical removal as well as patients with common variable immunodeficiency
(CVID) also do not respond to PPV 23 and suffer from recurrent infection caused by S
.pneumoniae.77 Studies have shown that these individuals are lacking a specific population
of MZ B cells known as IgM memory (IgM+CD27+IgD±).77 Somatically mutated IgM
memory B cells develop in the absence of germinal center and have a pre-diversified
antigen receptor repertoire which allows them to rapidly respond to TI-2 antigens without
T cell help. IgM memory B cells secrete natural IgM with anti-pneumococcal specificity
and serve as the first line of defense against pneumococcal pathogens.32,78 In humans, 30-
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60% of B cells express B cell memory marker CD27, a type I glycoprotein and a member
of the TNF receptor family. Based on the expression of CD27, B cells are characterized as
IgM memory and switched memory B cells (CD27+IgM-). Unlike IgM memory B cells
switched memory B cells have highly mutated VH sequence, are isotype switched and
originate from the germinal centers. Interestingly, switched memory B cells are present in
the blood of congenitally asplenic and splenectomized patients in normal frequencies.77
In summary, there is a strong correlation between the absence of IgM memory B
cells and impaired immune responses to encapsulated bacteria as seen in infants,
individuals with CVID and asplenic patients thus supporting the concept that IgM memory
B cells are major players in generating immune responses to TI-2 antigens.
1.6.2. Current Vaccination Recommendations for Adults
Pneumococcal vaccination recommendations are influenced by prevalence of
pneumococcal disease and trends in antimicrobial resistance. Both PCV13 (Prevnar 13,
Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.) and PPV23 (Pneumovax 23,
Merck and Co., Inc.) are currently licensed for use in the United States. The Advisory
Committee on immunization Practices (ACIP) recommends both PCV13 and PPV23 to be
given to immunocompetent adults aged over 65. ACIP recommends that a single dose of
PCV13 be given first followed by PPS23 6-12 months later. For individuals 65 or older
that have previously received a dose PPV23, ACIP recommends to receive a dose of
PCV13 at least one year later. Persons who previously received PPV23 before 65 years and
now are 65 or older, should receive a dose of PCV13 and one year later a dose of PPV23
but at least 5 years in between first and second doses of PPV23 (Table 1.1.)79. For adults
with immunocompromising conditions such as HIV+, ACIP determined that broader
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serotype protection can be achieved through use of a combination of both PCV13 and
PPV23. Studies have shown that the majority of IPD cases in immunocompromised adults
are caused by PCV13 serotypes, with an additional 21% caused by serotypes in PPV23 that
are not included in PCV13. HIV+ adults receive a single dose of PCV13 followed by a
single dose of PPV23 8 weeks later. All immunocompromised adults should receive a
second dose of PPV23 at least 5 years after their previous dose of PPV23 (Table 1.2.).79
The optimal interval between two vaccines has not been specifically studied, but a
significant increase in functional antibody production was observed when individuals
received PCV 7 followed by PPV23 at 8 weeks as compared to PPV 23 alone.80 Despite
available vaccinations the burden of pneumococcal disease among immunocompromised
adults remains high.
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Table 1. 1. Sequential administration and recommended intervals for 13-valent
pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal
polysaccharide vaccine (PPV23) for adults aged ≥65 years according to Advisory
Committee on Immunization Practices, United States

*

*Minimum

interval between sequential administration of PCV13 and PPSV23 is 8 weeks;
PPSV23 can be given later than 6–12 months after PCV13 if this window is missed.
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Table 1. 2. Sequential administration and recommended intervals for 13-valent
pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal
polysaccharide vaccine (PPV23) for immunocompromised adults aged ≥19 years
according to Advisory Committee on Immunization Practices, United States

Table 1.1. and Table 1.2. were adapted from Center for Disease Control, Treatment and Prevention.
Source: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6337a4.htm
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1.6.3. Limitations of pneumococcal vaccination in older adults and HIV+ individuals
Normal aging is characterized by functional changes in humoral and cellular
responses in the immune system that lead to increased susceptibility to infections, poor
response to novel vaccine antigens, loss of protection gained from previous vaccinations
and decreased immune surveillance resulting in increased incidence of autoimmunity and
cancer.81,82 Immunosenescence, defined as changes in the immune system due to aging, is
associated with immune activation and chronic inflammation which together promote agerelated decline of the functionality of the immune system. The main features of
immunosenescence include reduced function of macrophages, natural killer cells (NK), and
neutrophils, as well as thymic impairment, exhaustion of cellular immune capacity, and
reduction of T cell renewal.83,84 These characteristics clearly demonstrate a dysfunction in
both innate and adaptive immune responses which create a significant challenge in
developing effective vaccine formulations containing either TD or TI antigens for older
adults.
A number of studies documented decreased efficacy of PPV23 in the elderly as
compared to young adults.44,48,49,85 Although, serotype-specific IgG and IgM antibodies are
produced in response to the vaccine, their functionality is diminished.85 Furthermore, agerelated reduction in absolute number of IgM B cells also potentially contributes to reduced
responsiveness to pneumococcal vaccines.87,88
Increasing evidence suggests, that patients with HIV infection have similar
immunological changes as HIV-negative (HIV-) individuals who are decades older.
Indeed, HIV virus induced immunsenescence and chronic inflammation are thought to
mimic a premature aging process despite treatment with anti-retroviral drugs. T cell
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senescent phenotypes found in HIV as well increase in activated T cells, clonal exhaustion
and decreased levels of naïve regulatory T cells are also found in elderly HIV-negative
individuals. Likewise, the aging B cell system resembles that of HIV-positive (HIV+)
individuals in many aspects including polyclonal activation, hypergammaglobunimia,
activation of resting B cells, and memory cell depletion.84,89,90 Studies have shown, that
HIV+ individuals similarly to the elderly exhibit reduced antibody responses to
pneumococcal vaccination. In contrast to the elderly however, both serotype-specific IgG
and IgM antibody levels are diminished in HIV+. Furthermore, the functional antibody
capacity as measured by opsonophagocytic activity is also reduced.91,92,93
Poor responses to PPV23 in both the elderly and HIV+ are at least in part, related
to intrinsic B cell defects. Despite the fact that there is a considerable overlap in B cell
perturbations between the elderly and HIV+ including changes in B cell number, phenotype
distribution and reduced quality of B cell responses, studies in our laboratory have found
that aging and HIV result in distinct B cell deficiencies and phenotypes in response to
PPV23. In the elderly, the predominant phenotype in response to PPV23 consists of
switched memory B cells, while in HIV+ adults over the age of 50 it more closely
resembles the response of healthy young adults, expressing the IgM memory phenotype,
albeit at significantly lower levels. Furthermore, our recent studies strongly suggest that
the aging process in HIV+ persons does not follow the same pattern in response to PPV23
as noted in HIV- persons with a decrease in frequency and number of polysaccharide
specific (PPS-specific) IgM memory B cells and increase in frequency and number of PPSspecific switched memory B cells. These studies suggest that aging HIV+ persons might
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have unique immune responses to pneumococcal vaccination that remain to be
defined.87,92,93
1.7. Study objectives
The introduction of combined anti-retroviral therapy (cART) more than two
decades ago resulted in a significant improvement of life expectancy of HIV-positive
individuals leading to a rapid growth of aging HIV-positive population. In 2015,
approximately 47% of Americans living with diagnosed HIV were aged 50 and older. Of
these, 38% were aged 50-54, 29% were aged 55-59, and 34% aged 60 and older. In addition
to cART, the rates of newly diagnosed HIV infections in older adult also significantly
increased. CDC reports that people aged 50 and older accounted for 17% of new HIV
diagnoses in 2016. 36
Proper management of HIV infection eliminates the risk of AIDS and makes HIV
a chronic disease that requires a life-long access to therapy. Despite successful treatment,
HIV-positive individuals undergo numerous immunological changes and display increased
incidence of age related co-morbidities including cardiovascular disease, metabolic
disorders, cancer, and renal disease that occur at a younger age as compared to uninfected
persons.95,96,97 Combination of aging and HIV presents special challenges in preventing
other diseases including infections caused by S. pneumoniae, a major cause of morbidity
and mortality in individuals infected with HIV.35,98,99 Therefore, maximizing the efforts to
prevent pneumococcal infections in HIV+ individuals is important. Pneumococcal
vaccinations are routinely recommended however, as previously discussed, despite the
fact, both HIV and elderly respond poorly to pneumococcal vaccines due to B cell
dysfunction and mechanisms that are not well defined.
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This study was designed to define the specific B cell immune defects associated
with poor pneumococcal vaccine responses in aging HIV+ persons as compared to young
HIV+ and age-matched HIV- individuals. We postulated that in HIV+ persons, aging of
the B cell compartment was unique and different as compared to HIV-negative persons and
did not simply reflect a “premature” or accelerated aging process but rather a combination
of HIV and aging. We extensively characterized the immune response of HIV-positive
individuals to pneumococcal vaccination according to two age groups 21-40 and 50-65
years old and compared these groups to age and co-morbidity matched HIV- negative
controls. We focused our studies on HIV+ persons with nadir CD4 >200 only.
The execution of this research contributed to a greater understanding of B cell
immunity and inflammation in aging HIV+ individuals, who represent a unique population
burdened with two distinct processes: aging and HIV. Furthermore, elucidation of the
relationship between HIV disease and aging could have far reaching translational and
treatment implications for the elderly and HIV+ persons. This is also the first study, to our
knowledge, to characterize IgM memory B cells on a single cell level in these high-risk
groups.
The principal goal of this study was to evaluate inflammatory milieu,
antibody production and functionality in aging HIV+ individuals as compared to
HIV- age and co-morbidity controls and to characterize individual cellular
changes in order to identify variations in inter-cellular gene expression that
shape polysaccharide–specific B cell responses and determine how aging affects
these gene expressions.
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The studies and their objectives are summarized below:
1. To determine how the B cell response to pneumococcal vaccination changes
with age in HIV-positive individuals as compared to HIV-negative agematched controls by evaluating serum and functional antibody responses.
a. Assessment of quantitative responses to pneumococcal
b. Assessment of functional antibody responses
c. Assessment of correlation between quantitative and qualitative antibody
responses
2. To determine if there are race-related differences in functional antibody
responses in HIV+ individuals
a. Assessment of antibody and functional antibody responses in African
American HIV+ and Caucasian HIV+ individuals
b. Phenotypic analysis of IgM memory B cells before vaccination
3. To examine the expression of inflammatory markers and intrinsic B cell
defects in HIV+ individuals pre-pneumococcal vaccination.
a. Define the nature of the inflammatory status and elucidate its potential
consequences of correlation with functional antibody response.
b. Extensively characterize the phenotype and expression of specific genes
with known or likely role in response to pneumococcal vaccination and cell
function in unselected pre-immunization and PPS-selected postimmunization IgM memory B cells, crucial in response to PPS using flow
cytometry and single cell genomics.
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1.8. Design and Study Population
Study volunteers were recruited at the University of Toledo Medical Center or at
the Medical University of South Carolina (MUSC) over the course of six years from 20132019. The study was monitored and approved by the Institutional Review Board (IRB) at
the University of Toledo and the Institutional Review Board at MUSC. Written informed
consent was obtained from all subjects (Table1.3.). Exclusion criteria included: active
infection (except HIV), PPV<5 years prior, pregnancy, history of autoimmune disease,
cancer, organ transplantation, splenectomy, end stage kidney or liver diseases,
immunoglobulin therapy, bleeding disorders. Volunteers were questioned about any prior
hospitalizations consistent with pneumococcal infection. Eligibility criteria for all HIV+
individuals were defined as undetectable viral loads (≤400 copies/ml), CD4> 200 cells/µl
and ART for at least 1 year. HIV+ cohorts had a history of PPV vaccination at least 5 years
prior to study enrollment. Volunteers received a single dose of PCV13 followed by a single
dose of PPV23 8 weeks later (PCV/PPV); HIV- individual in 21-40 age-group followed a
different vaccination protocol based on ACIP recommendations; they received a single
dose of PPV23 (Fig. 1.1.). Young HIV- persons did not have a history of previous
immunization with pneumococcal vaccine and have been enrolled in the study to serve as
positive control based on the previous studies that showed that this age groups
demonstrates high response rates to pneumococcal vaccines.45
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Table 1. 3. Baseline Characteristics of Study Participants

HIV-infected

Characteristic

HIV-uninfected

Young

Aging

Young

Aging

PCV13/PPV23
(N=12)

PCV13/PPV23
N=21

PPV23
(N=59)

PCV13/PPV23
(N=15)

Demographic
Mean age (range)

31(24-40)

54 (50-65)

27 (21-42)

56 (52-65)

Male (%)

9(75)

16(76)

39(66)

7(46)

African American

6(50)

10(48)

16(29)

1(7)

Caucasian

6(50)

11(52)

42(71)

14(93)

Clinical History
Prior PPV≥5 years
(%)

12(100)

21(100)

0(0)

0(100)

Receiving ART≥ 1
year (%)

12(100)

21(100)

N/A

N/A

395

280
N/A

N/A

Nadir CD4 count
(cells/µl) Mean
(range)

(222-748)
(200-938)
Laboratory Data at Enrollment

CD4 T cell count
(cells/µl)
Mean (range)

608
(375-1299)

689
(331-1298)

N/A

N/A

HIV viral load
(copies/ml)≤40(%)

12(100)

21(100)

N/A

N/A
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Figure 1. 1. Timeline for blood sample collection and vaccine administration.
Individuals who received PPV23 had three blood collections: day 0 prior to
immunization, day 7, and day 30 post immunization. Individuals who received PCV13
followed by PPV23 had 5 blood collections: day 0, day 7 post-PCV13, day 56 (prior to
PPV23), day 63 (7 days post PPV-23), and day 90 post-immunization.
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Chapter 2
Serum and functional antibody responses to pneumococcal vaccination in young and
aging HIV+ adults
2.1.Introduction
Streptococcus pneumoniae is a major cause of morbidity and mortality in
individuals infected with human immunodeficiency virus (HIV+).1 An increased incidence
of pneumococcal infection is also common among the elderly over the age of 65.2 As a
preventative strategy, the pneumococcal vaccination is routinely recommended for HIV+
persons and the elderly. However, the pneumococcal polysaccharide vaccine (PPV) is
poorly efficacious, especially in individuals with nadir CD4 count below 200 and certain
cohorts of the aging population.3,4 This is likely caused by humoral dysfunction and
significant perturbations in B cell immunity caused by HIV-disease and aging.5 Similar to
advanced age, HIV infection is associated with chronic inflammation and alterations in B
cells such as polyclonal activation, activation of resting B cells, chronic inflammation, and
memory cell depletion. Indeed, HIV disease is proposed as a model of premature
immunoaging.6,7,8,9 However, the question whether immunological changes caused by HIV
infection synergize with normal aging process and have a combined effect on immune
response to pneumococcal vaccination remains unanswered.
The goal of this study is two-fold: 1) to evaluate immune responses to
pneumococcal vaccination in well-defined (cART, HIV viral load, nadir CD4 count) HIV+
persons according to age group from 21-40 versus 50-65 and compare these groups to agematched HIV-negative controls by measuring serum antibody and functional antibody
responses; 2) to understand the effect of aging plus HIV on B cell function.
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2.2.Methods
ELISA
Blood samples were collected at days 0 pre-immunization and day 30 postimmunization for PPV23 only recipients and days 0, 63, and 90 for the PCV13/PPV23
recipients. Serum samples were used to measure pneumococcal capsular polysaccharidespecific IgG and IgM responses pre- to 1-month post-immunization with PPV23 and preto 90 days post-immunization with PCV13/PPV23. Serotype-specific IgG and IgM levels
were detected by enzyme-linked immunosorbent assay (ELISA). This method has been
approved by the World Health Organization (WHO) for quantification of human IgG and
IgM antibodies specific for Streptococcus pneumoniae capsular polysaccharides (Pn PS)
and was performed in accordance with the training manual published by WHO.10,11 Briefly,
human serum samples and control serum were pre-absorbed with common cell wall
polysaccharide (CWPS) and capsular polysaccharide 22F. The pre-absorption is performed
in order to neutralize antibody binding to CWPS and other common contaminates
generated during type-specific polysaccharide purification. 22F is used because it is a rare
serotype and it is not present in either PCV13 nor in PPV23 and it is thought to contain
contaminating non-Pn PS epitopes. 007sp was used as a serum reference standard/control.
007sp is a pooled serum obtained from 287 healthy volunteers following vaccination with
PPV23.12 The concertation of 007sp was defined through bridging to the previously
established serum 89SF. ELISA Nunc Maxisorp 96 well-plate was coated with 15 µg/ml
Pn PS serotype 14 or 23F and incubated overnight at 37°C. Absorbed plate was washed
with wash buffer (1X PBS, 0.05% Tween 20) and then blocked (1X PBS/1%BSA buffer)
for 1 hour. Next, serially diluted sera were added on the plate and incubated at 37°C for 2
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hours. Following the incubation, the plate was washed, and bound antibody was detected
using hourseradish peroxidase (HRP)-conjugated anti-human IgG and IgM. The serotypespecific antibodies bound to the ELISA plate were developed using o-phenylenediamine
substrate and read at 490 nm on a microplate reader. Linear regression fits were used to
determine the antibody concentrations, and these were reported as µg/ml.
Functional PPS-specific antibody titers
Opsonophagocytic assay (OPA) was performed using pre- and post-vaccination
samples according to protocol for multiplexed opsonophagocytic killing assay (UABMOPA) for antibodies against Streptococcus pneumoniae.13 Briefly, serially diluted heatinactivated donor sera and target bacteria (serotype 14 or 23F) were added to 96-well
microtiter plates. The reaction mixture was incubated for 30 minutes while shaking at room
temperature. HL-60 cells, which were differentiated into granulocytic cells by culturing
them in RPMI-1640 with 10% fetal bovine serum (FBS) and 0.8% dimethylformamide
(DMF) for 5-6 day and resuspended in Hanks’ buffer supplemented with 0.1% gelatin and
10% FBS in concertation 106 cells/ml were added together with newborn rabbit
complement. Final reaction mixture contained donor serum, serially diluted bacteria, HL60 cells with rabbit complement and was incubated for 45 minutes at 37°C with shaking.
007sp was used as a positive control. 10 µl of the reaction mixture from each dilution was
plated on a Todd-Hewitt-yeast extract agar plate (THYA plate) and incubated at 37°C
overnight. Bacterial colonies were counted and the opsonophagocytic titer was determined
as the reciprocal of the dilution with 50% killing when compared with serum free controls
and analyzed using Opsonotiter1 software developed by the University of Alabama at
Birmingham.
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Statistical analysis
Participant characteristics were represented as mean (range) for numerical values
and number (percentage) for categorical value. Serotype-specific IgG and IgM (µg/ml) and
OPA titers were reported as geometric mean concentrations or titers (95% confidence
interval), respectively. OPA titers were log-transformed. Pre- and post-vaccination data in
a single group were analyzed using paired t-test. Group comparisons were performed using
Wilcoxon rank-sum test. Correlations between the groups were examined using Pearson
correlation. P-values <0.05 were considered statistically significant. Statistical analysis
was performed using GraphPad Prism software.
2.3.Results
Serum anti-PPS antibody levels to serotype 14 and 23F in young and aging HIV+
groups as compared to age- and comorbidity matched HIV- groups.
Pre- to post- vaccination serum IgM and IgG levels significantly increased in all groups for
both serotype 14 and 23F, with the exception of young HIV+ group, which did not
demonstrate a significant increase in serum IgG antibody titer to serotype 23F. Postvaccination antibody levels were compared among all four groups. Young HIVindividuals had significantly higher levels of IgG and IgM serum antibody levels to
serotypes 14 and 23F as compared to aging HIV-, young and aging HIV+ groups (Fig.2.1).
There were no differences in the immune response between young HIV+ and aging HIV+
groups, however, serum IgM levels to serotype 14 and serum IgG levels to serotype 23F
were significantly higher in the aging HIV- group as compared to aging HIV+ group
(p=0.0009 and p=0.01 respectively).
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Figure 2. 1. Polysaccharide-specific serum antibody levels to serotypes 14 and 23F.
Serum IgM and IgG serum antibody levels were measured in young and aging HIV+
individuals and age-matched HIV- negative individuals pre- and post-immunization with
pneumococcal vaccination. Changes in serum antibody levels in a single group were
compared using paired t-test and changes between the groups were compared using
Wilcoxon sign rank t-test. P-values <0.05 were considered significant. *p<0.05, **<0.01,
***p<0.001
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Serum OPA titers to serotypes 14 and 23F
Significant increase in OPA titers from pre- to post pneumococcal vaccination
occurred in all groups. Post-vaccination OPA titers were compared among the groups.
Young HIV- group demonstrated significantly higher OPA titers as compared to young
and aging HIV+ groups and aging HIV- groups. There were no significant differences in
OPA titers between young HIV+ and aging HIV+ groups, or aging HIV+ as compared to
aging HIV- groups (Fig. 2.2).

Figure 2. 2. Serum OPA titers to serotypes 14 and 23F. Serotype-specific OPA titers
were determined in young and aging HIV+ individuals pre- and post-vaccination and
compared to age and co-morbidity matched young and aging HIV- individuals. Changes in
OPA titers in a single group were compared using paired t-test and changes between the
groups were compared using Wilcoxon sign rank t-test. P-values <0.05 were considered
significant. *p<0.05, **<0.01, ***p<0.001
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Correlation between post-vaccination levels and OPA titer
A significant correlation was observed between post-vaccination serotype-specific
IgG levels and OPA titers for serotype 23F in young HIV- group (r=0.2, p=0.04) and aging
HIV- group (r=0.63, p=0.008) and for serotypes 14 in young HIV+ groups (r=0.79,
p=0.01), aging HIV+ group (r=0.67, p=0.01) and aging HIV- group (r=0.62, p=0.002). In
other groups, poor negative (IgM) and moderate positive (IgG) correlations were observed
between OPA titers and antibody levels post-vaccination, however, the relationship was
not statistically significant (Fig. 2.3-2.4).
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Figure 2. 3. Correlations between post-vaccination antibody levels and OPA titers in
HIV- and HIV+ groups for serotype 14.
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Figure 2. 4. Correlations between post-vaccination antibody levels and OPA titers in
HIV- and HIV+ groups for serotype 23F.
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2.4.Discussion
Advancement in treatment options and introduction of combined anti-retroviral
therapy (ART) has significantly increased the lifespan of HIV+ individuals resulting in a
rapid growth of the aging HIV+ population.14,15,16 HIV disease is characterized by
numerous changes and defects in humoral immune responses including chronic
inflammation and increased susceptibility to pneumococcal infections. Independent of
HIV, advanced age is also associated with reduced functionality of the immune system,
poor response to novel vaccine antigens and decreased immunesurveillance.17,18,19 We have
previously reported that although both HIV+ and the elderly respond to PPV23 vaccine,
the levels of serotype specific IgG and IgM antibodies are low.20,21,22,23
The primary objective of the current study was to test the hypothesis that changes
in B cell immunity in aging HIV+ persons are unique combination of two distinct processes
that accumulate over the lifetime of the HIV+ individual and do not simply represent aging
on the background of premature aging. We studied changes in B cell response in young
and aging HIV+ individuals by evaluating serum antibody levels and functional antibodies
after receiving PCV13 followed by PPV23 vaccination regimen and compared these
responses to age-matched HIV- persons.
Two serological methods were used to evaluate the efficacy of pneumococcal
vaccine: ELISA and OPA10,24 Our results demonstrate a significant increase in serotypespecific IgG and IgM antibody levels post-vaccination in all groups with the exception of
the young HIV+ group, which did not demonstrate a significant increase in IgG antibody
levels to serotype 23F only. Although the increase in antibody production was significant,
the results clearly show that immunological response in high risk groups (HIV+ and aging
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HIV-) was suboptimal as compared to young HIV- group. Furthermore, serotype-specific
levels of IgM antibodies were generally low in high risk groups. In agreement with other
studies, we show that natural anti-CPS IgM (pre-immunization) declined with age and HIV
infection. This is an important observation because antipneumococcal immunity is
mediated via IgM, which promotes innate immune response by activating the classical
complement pathway.25 Aging HIV- individuals demonstrate a prominent reduction in the
ability to respond to pneumococcal vaccination as compared to healthy young HIV- adults.
A similar phenomena however, was not observed in HIV+ groups; there were no significant
differences in serotype-specific serum antibody levels between young HIV+ and aging
HIV+. Furthermore, aging HIV+ group displayed contrasting response as compared to
aging HIV- groups. Levels of IgM antibody against serotype 14 and IgG antibody against
serotype 23F were dramatically decreased in aging HIV+ individuals as compared to aging
HIV- individuals but were similar between aging HIV- and young HIV+. Collectively,
these findings suggest that antibody response to pneumococcal vaccination in aging HIV+
is unique and follows a distinct pattern.
However, immune response in high risk populations cannot simply be measured by
one surrogate marker of protection such anti-capsular PS antibody levels. Studies have
shown that both aging HIV- and HIV+ persons produce antibodies with reduced specificity
and affinity resulting in poor recall and novel antigen responses. Furthermore, antibody
concentration does not always correlate with functionality. Nonspecific antibodies are
nonprotective and often times contribute to a large portion of measured concentration in
the standardized PPS ELISA in high risk populations.26 Therefore, opsonophagocytic assay
is generally regarded as a better correlate of protection.25,27 Unlike ELISA, OPA mimics
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the natural host defense responses and tests the functional ability of vaccine induced
antibodies to drive efficient complement deposition necessary for opsonic clearance of
pneumococci in vivo.28 We performed OPA to measure functionality of antibodies
produced in response to serotypes 14 and 23F. Similarly, to results obtained from ELISA,
all groups demonstrated significant increase in OPA titers post-vaccination. Young HIVgroup had the highest OPA titers (OPT) for both serotype 14 and serotype 23F as compared
to HIV+ groups and aging HIV- groups. Interestingly, high risk groups displayed a high
degree of variation in post-immunization OPA titers, ranging from very low responses to
high responses that were comparable to HIV- young adults. It is speculated, that in aging
groups, higher titers were unlikely to be vaccine-induced, but rather raised from innate
opsonins against serotype 14 and 23F.29 Variations and differences in correlation between
antibody levels and OPT post-vaccination to different serotypes are consistent with the
literature and further reinforces the need to include OPA assay in the studies.26,30
To our knowledge, this is the first study to examine how the aging process impacts
immune response to pneumococcal vaccination in HIV+ individuals. This study however,
has several limitations. The sample size was small, limiting the power of the study. We are
reporting immune response to only 2 serotypes, therefore it is unknown if similar results
would be observed for other serotypes. Furthermore, unlike other study groups, the young
HIV- group did not receive Prevnar13 prior to receiving Pneumovax23. In general, healthy
young adults are not required to receive pneumococcal vaccination because they are not
considered to be at high risk of IPD. This group served as positive control and as a reference
of a robust immune response. Lastly, unlike HIV+ subjects, both cohorts of HIV- study
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participants were not previously vaccinated with Pneumovax23, therefore study results
must be interpreted with care.
Serotypes 14 and 23F were selected for the study because: 1) both represent clinical
pathogenic serotypes that can result in invasive disease, 2) are present in PCV13 and
PPV23, 3) vary in immunogenicity from high (PPS14) to moderate 23F.
Overall, we report significant differences between pneumococcal vaccine
responses in young HIV- and aging HIV-, however no significant differences were found
between young and aging HIV+ groups suggesting that perhaps HIV infection rather than
age in the HIV-infected person, has a considerable impact on immune response to
pneumococcal vaccination. Future immunogenicity studies will evaluate the phenotype of
B cells that respond to vaccines antigens in order to determine if PPS-B cell phenotype
changes with age in young and aging HIV+ adults.
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3.1. Introduction
Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide.
Prior to the introduction of pneumococcal conjugate vaccines in 2000, S. pneumoniae
caused 500,000 cases of pneumonia, 50,000 cases of bacteremia, and 3,000 cases of
meningitis per year in the United States alone, resulting in 40,000 deaths1. Since the
institution of routine childhood vaccination with the pneumococcal conjugate vaccine,
there has been a dramatic reduction in incidence of pneumococcal disease. Nevertheless,
pneumococcal disease remains a major cause of community acquired pneumonia

2

and

invasive pneumococcal disease (IPD) is still responsible for more than 3100 deaths yearly
in adults in the US alone 3.
Although age is an important risk factor for IPD, a number of other factors are
known to increase the risk for IPD in adults. These include ethnicity, 4 low socioeconomic
status, chronic underlying diseases such as chronic obstructive pulmonary disease (COPD),
heart disease, diabetes and renal disease, and high risk behaviors such as smoking and
alcohol abuse.5 ,6 7,8
Furthermore, a number of immune deficiencies4, 7,9,10,11 including HIV, increase the risk of
IPD significantly. Moreover, despite the widespread availability of antiretroviral therapy,
HIV-infected individuals remain at a 35-fold increased risk of IPD compared to agematched HIV-negative. 10
A disproportionately high number of African American (AA) individuals are
affected by HIV in the USA. Although only 12% of the US population is African American,
43% of the total number of persons living with HIV in the US are African American.11
Several studies have shown that African American race is also associated with increased
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incidence of IPD in the HIV positive population similar to the observation made in HIV
negative individuals.12,13,14 We, and others, have previously shown that the immune
response to both pneumococcal polysaccharide (Pneumovax®) (PPV) and conjugated
polysaccharide (Prevnar®) (PCV) vaccines are suboptimal in the HIV positive adult
populations.15,16,17,18,19 It has been suggested that poor immune response to pneumococcal
polysaccharides may contribute to the race related increased incidence of IPD in African
American HIV positive individuals14,20. A recent prospective study that compared pre- to
post-immunization capsule-specific IgG levels for 4 serotypes in AA versus Caucasian
HIV-positive individuals failed to demonstrate race-related differences in immune
response. 21
However, poor correlations between IgG antibody concentration and functional or
opsonophagocytic antibody activity in adults have inferred that OPA is a more accurate
surrogate of protection.22
We report the immune response to 3 pneumococcal serotypes before and after
revaccination with either PPV alone or PCV followed by PPV in Caucasian and AA HIVpositive adults by measuring both serum antibody levels and OPA as well as inflammatory
markers before vaccination. Furthermore, we utilized systems biology approach to examine
whether differential gene expression on the single cell level, has an impact on production
of functional antibodies.
3.2. Methods
Design and Study Population. HIV-positive subjects were recruited at the University of
Toledo Medical Center or at the Medical University of South Carolina (MUSC). The study
was monitored and approved by the Institutional Review Board (IRB) at the University of
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Toledo and the Institutional Review Board at MUSC.

Written, informed consent was

obtained from all subjects. HIV positive individuals who agreed to participate in the study
were randomized using a random assignment generator to receive either PCV/PPV (days
0 and 56) or PPV (day 0) alone; individuals who agreed to participate in the study but were
receiving vaccination as a part of routine clinical care were assigned and analyzed in their
respective groups based on vaccination regimen in a non-randomized manner.
Consequently, there was a smaller number of participants in PCV/PPV Caucasian group as
compared to African American group. The study participants were enrolled over the course
of 4 years from 2013-2017. Exclusion criteria included: active infection (except HIV),
PPV <5 years prior, pregnancy, immunosuppressive medications, and history of cancer,
autoimmune disease, bleeding disorders, immunoglobulin therapy, organ transplantation,
splenectomy, and end stage renal or liver disease. Volunteers were questioned about any
prior hospitalizations consistent with pneumococcal infection. Eligibility criteria for HIV+
participants were further defined as CD4>200 cells/ul at the time of vaccination (Day 0),
regardless of nadir CD4 count history (Table 1), HIV viral load ≤ 400 copies/ml, and ART
for ≥ 1 year. All subjects had previously been immunized with PPV (≥5 years earlier).
HIV+ individuals received either PCV/PPV (days 0 and 56) or a single dose of PPV
(day 0).
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Table 3. 1. Baseline characteristics of study participants

Race
Characteristic

African American (AA)
PPV (n=15)

PCV/PPV
(n=13)

Caucasians (Cau)

PPV&PCV/PPV
(n=28)

PPV(n=20
)

PCV/PPV
(n=8)

PPV&PCV/PP
V (n=28)

Demographic
Mean Age (range)

51.2 (4462)

53.2(4063)

52(40-63)

52.1(4264)

54.9(5060)

52.8(42-64)

Male %

12(80)

11(85)

23(82)

19(95)

8(100)

27(96)

Clinical History

Prior PPV≥ 5 years (%)

Receiving ART≥1 year
(%)

15(100)

13(100)

28(100)

20(100)

8(100)

28(100)

15(100)

13(100)

28(100)

20(100)

8(100)

28(1000

Laboratory Data

HIV viral load
(copies/ml)<400 (%)
CD4 T cell count
(cells/ul)
Mean current
(Range nadir)

14(93)

13(100)

27(96)

20(100)

8(10)

28(100)

442
(102-852)

336
(76-938)

393
(76-938)

324
(26-896)

218
(4-455)

294
(4-896)

Antibody ELISA.
Blood samples were collected at days 0 (pre-immunization) and 30 for PPV only
recipients and days 0, 63 and 90 for the PCV/PPV recipients. Serum samples were used to
measure pneumococcal capsular polysaccharide-specific IgG responses pre- and 1 month
post-vaccination with PPV (post-PPV) to serotypes 14, 19A and 23F. Serotype-specific
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IgG and IgM serum levels were detected by enzyme-linked immunosorbent assay (ELISA)
as previously described. 23,16
Opsonophagocytic Assay
Opsonophagocytic killing assay (OPA) was performed as previously described 24,16
to determine functional antibody responses. Data were analyzed using the Opsotiter1
software program (University of Alabama at Birmingham). OPA titers were defined as the
reciprocal of the serum dilution that killed 50% of target bacteria (compared to serum-free
control) during 45 minutes of incubation at 37ºC.
Inflammatory marker analysis
Luminex analysis of 10 inflammatory markers, BAFF, APRIL, IL-10, IL-1Ra, IL8, IL-6, sCD40L, IP-10, IL-1B, and TNF-alpha, was performed on pre-immunization
serum samples obtained from all participants by EveTechnologies (Calgary, AB, Canada).
Single Cell qPCR
Single cell gene expression experiments were performed using Fluidigm 96.96
qPCR Dynamic Array microfluidic chips and HD Biomark. Peripheral blood mononuclear
cells (PBMC) were collected from African American and Caucasian volunteers prevaccination on day 0 and stained with fluorochrome-conjugate mAbs using the following
anti-human antigens: CD19, CD27, and IgM. IgM memory B cells (CD19+CD27+IgM+)
were sorted using Beckman Coulter MoFLo Astrios sorter. Single IgM memory B cell
capture and specific target amplification were carried out using Fluidigm C1 Single Cell
Auto Prep System and Single Cell Auto prep array Integrated Fluidic Circuits (IFCs). Chip
priming, cell loading, lysis, reverse transcription and pre-amplification was performed
according to Fluidigm’s recommended protocol. Pre-amplified cDNA samples from single
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cells were analyzed by qPCR using 96.96 Dynamic array IFC and the Biomark HD system
and DELTA gene assay (Fluidigm) designed for 64 human transcripts.
Statistical Analysis
Participant characteristics were represented as mean (range) for numerical values
and number (percentage) for categorical values. Serotype-specific serum IgG, IgM (µg/ml)
and OPA titers were reported as geometric mean concentrations or titers (95% confidence
interval), respectively.

IgG, IgM levels and OPA titers were log-transformed to

approximate normal distribution prior to statistical analysis. Pre- to 1-month postvaccination comparison within the groups were calculated using paired t-test; differences
within the groups were calculated using Wilcoxon rank-sum test. Correlations were
determined by Pearson’s correlation coefficient. All statistical analyses were performed
using Prism software (GraphPad). Single cell qPCR data was analyzed using Fluidigm
Real Time PCR analysis software with Auto Ct Threshold method and also Singular
package for R. ANOVA was performed and violin plots of differentially expressed genes
that were ranked by p-value were created. P values < 0.05 were considered significant.
3.3. Results
Subjects
Baseline characteristics of the 56 participants (28 Caucasian and 28 AA) included
in this study are shown in Table 1. We analyzed each racial group according to vaccination
protocol (PPV alone, PCV/PPV or two groups combined: both PPV and PCV/PPV shown
in graphs as post-vaccination). Age, CD4 counts at enrollment and HIV viral load were
similar between the two ethnic groups and vaccination protocols. All individuals were
treated with ART ≥1 year. All participants had been immunized with PPV ≥ 5 years prior.
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Serum antibody levels to serotypes 14, 19A and 23F post both PPV and PCV/PPV.
Post-vaccination IgG levels were significantly higher in all groups and for all
serotypes as compared to pre-vaccination levels, however IgM levels to PPS14 were
significantly higher only in Caucasian group but not in AA group pre-to post vaccination
(Figure 3.1). Serum IgM concentrations to serotype 19A were not measured because a
reference serum standard is not established. There were no significant differences in either
pre- or post-vaccination IgG and IgM antibody concentrations between AA and Caucasians
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Figure 3. 1. Polysaccharide-specific serum antibody levels to serotypes 14, 23F and
19A. Serum IgG and IgM antibody responses tested for PPS14, PPS23F, and 19A in
Caucasian and African American HIV-positive individuals pre- and post-immunization
with Pneumovax-23 (PPV) or Prevnar-13 /Pneumovax-23 (PCV/PPV). Changes in serum
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antibody levels in a single group were compared using paired t-test and changes between
the groups were compared using Wilcoxon sign rank t-test.

Serum OPA titers to serotypes 14, 19A and 23F
Significant increases in serotype-specific OPA titers were observed in all
vaccination regimens for both AA and Caucasian groups (Figure 3.2). There were no
differences in baseline OPA titers between the groups/vaccination regimens. However,
post-immunization OPA titers were significantly higher in the response to PPS14 in all
Caucasian groups, regardless of immunization protocol compared to the AA groups. OPA
titers to PPS19A were also significantly higher in the Caucasian versus AA group
immunized with PPV only, however in response to PCV/PPV there was no significant
difference between ethnic groups. In response to PPS23F there were no detectable
differences in OPA titer in any of the groups, irrespective of race or immunization strategy.
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Figure 3. 2. Serum OPA titers to serotypes 14, 23F, and 19A. Serotype-specific serum
OPA titers were determined in HIV-positive Caucasian and African-American individuals
pre-and post-vaccination with either A-Pneumovax-23 (PPV) or B-Prevnar-13
(PCV)/Pneumovax-23 (PCV/PPV). All Caucasian versus African American participants in
groups A and B together depicted in C. Changes in OPA titers in a single group were
compared using paired t-test and changes between the groups were compared using
Wilcoxon sign rank t-test.
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Correlations between post-PPV antibody levels and OPA titers
In the post-immunization response to PPS14 the AA and Caucasian HIV+ groups
showed a good correlation between anti-PPS14 IgG and OPA with r2=0.66 with p=0.00002
for AA group and r2=0.45 with p=0.016 for Caucasian group (Figure 3.3).
The correlation between post-vaccination IgG antibody concentration and OPA in response
to PPS19A was significant in the AA (r2=0.51, p<0.006) but not in Caucasian group
(r2=0.2, p>0.3) There was no significant correlation between post-vaccination IgG
antibody response and OPA in response to PPS23F for both Caucasian group and AA
group, regardless of vaccination strategy.
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Figure 3. 3. Correlation between post-vaccination IgG antibody levels and OPA titers
in all HIV-positive African-American and Caucasian individuals regardless of
vaccination protocol. Correlations were determined by Pearson’s correlation
coefficient.
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Inflammatory profiles
We measured a total of 10 inflammatory markers: BAFF, APRIL, IL-10, IL-1RA,
IL-8, IL-6, sCD40L, IP-10, IL-1B, and TNF-alpha in pre-immunization serum of HIVpositive individuals in both cohorts to define inflammatory activity and its potential
consequences or correlation with functional antibody activity. We compared each
inflammatory marker in the group of Caucasian participants against the group of AA
participants. We found no significant differences in any of the measured inflammatory
markers measured between groups (Figure 3.4).

IL-1RA
200

15

Serum concentration, pg/ml

Serum concentration, pg/mL

IL-1B

10

5

0

African Americans

150

100

50

0

Caucasians

600

400

200

0

African Americans

Caucasians

TNF-a
Serum concentration, pg/ml

Serum concentration, pg/mL

IP-10

African Americans

Caucasians

52

30

20

10

0

African Americans

Caucasians

IL-6

IL-8
Serum concentration, pg/ml

Serum concentratio, pg/ml

6

4

2

0

African Americans

150

100

50

0

Caucasians

Serum concentration, ng/ml

3000

2000

1000

0

African Americans

Caucasians

BAFF

4000

Caucasians

8

6

4

2

0

African Americans

Caucasians

IL-10
Serum concentration, pg/ml

Serum concentration, pg/ml

APRIL

African Americans

25

Figure 3. 4.Serum cytokine and
chemokine levels. Serum inflammatory
markers were measured using Luminex
assay in HIV-positive African-American
and Caucasian individuals prior to
immunization. Difference between the
groups were compared using Wilcoxon
sign rank test; no significant differences
were found.

20
15
10
5
0

African Americans

Caucasians

53

Single Cell qPCR
We performed single cell gene expression profiling on a specific subset of IgM
memory B cells that play an important role in T-cell independent immune response at the
baseline before vaccination. Results from our study have shown that there are significant
differences between IgM memory subsets isolated from Caucasian and AA groups in terms
of gene expression levels (Figure 3.5.). We have found that there are 33 genes that are
differentially expressed between AA and Caucasian groups, including genes involved in
metabolic activity (HK2, PFKP, LDHA, ENTPD1, ENO1, TYMS), lymphocyte signaling
(MS4A1, FCRL2, CD1D, CXCL8, CD80, CBLB, RFTN1, CD40, CCR2), T-cell
independent immune response (BAFF-R, TLR1, IL21R, TLR4), transcription factors
(SPIB, IRF4, PAX5, IKZF3, BCL6, FOXO1), apoptotic activity (BCL2, BIK, MCL1,
BAX), as well as cytokine and receptors (IL6, IL-7, INFGR). Gene expression levels were
significantly higher in AA as compared to Caucasians. Interestingly, despite overall higher
levels of expression of these genes, the bimodal distribution was more frequently observed
in AA group as compared to Caucasian group.
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Figure 3. 5. Multimodal variation in gene expression levels. Violin plots of differentially
expressed genes that are ranked by p-values. 64 genes were examined in pre-immunization
IgM memory single B cells isolated from HIV-positive African-American and Caucasian
individuals.
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DISCUSSION
It has been well established that race is a significant risk factor in IPD in both HIV
negative and HIV positive populations. 4,12,14,25 A retrospective case controlled study of
HIV positive adults with pneumococcal disease found that pneumococcal disease was more
common in African American HIV positive persons compared to HIV positive persons of
other ethnicities14. Moreover, the 23-valent pneumococcal polysaccharide vaccine
(PPV23) efficacy was markedly better, 76% in Caucasians, compared to black patients,
24%, despite similar CD4 T cell counts.14 Similarly, French et al found that PPV23 was
ineffective in a HIV-infected African population.20 Based on these studies, it has been
speculated that poor immunological response to pneumococcal polysaccharides may be in
part responsible for this racial bias. A recent study however, reported no differences in
PPS-specific IgG response between Caucasian and AA participants,21 but functional
antibody studies were not performed.
Although serological criteria for evaluation of pneumococcal vaccines in infants
have been established, the correlates of protective pneumococcal immunity in adult
populations have yet to be determined.26 The opsonophagocytic assay (OPA) is generally
regarded as a better measure of protection compared to antibody concentrations as it
mimics the host phagocytic, or functional, response.22,27 Correlations between serum IgG
antibody and OPA tend to vary greatly and are generally low in the elderly.28 Moreover,
PPS-specific IgM antibody concentrations also contribute significantly to OPA activity.29
Based on the observations that both PPS-specific IgM and IgG opsonize pneumococci, and
OPA appears to be the best correlate of protection. Here, we report an evaluation of the
immune response to pneumococcal vaccination to 3 serotypes by measuring the PPS-
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specific IgG and IgM concentrations and OPA in HIV-positive African American and
Caucasian individuals. The participants in our study were selected for participation in this
study based on age (40-65 years), CD4 T cell count, low/undetectable HIV viral load and
duration of ART, as each of these factors can influence vaccine responses.16, 17, 29,30, 31 We
studied the immune response to the common clinical pathogens serotypes 14, 19A, and 23F
as these serotypes are: 1. included in both PCV13 and PPV23, 2. represent both negatively
charged and neutral polysaccharides, 3. Vary in immunogenicity, generating high (PPS14)
to moderate (PPS23F) to moderately low (19A) immune responses and 4. have been widely
studied in various populations in our laboratory with ample well standardized samples
available for controls (14 and 23F) or 5. are important emerging serotypes (19A). We also
examined immune responses to poorly immunogenic serotypes such as serotype 3, a
serotype with low invasive potential, but high reported mortality rates and 7F, a serotype
with very high invasive potential. However, as expected, the response rates in both groups
were very low and there were no significant differences in OPA titers between ethnic
groups (unpublished data). Serotypes that classically induce poor immune responses are
less suitable for studies in what is expected to be a low responding population(s).
Although all participants were previously immunized with the 23-valent PPV and
could potentially have various amounts of residual (functional) antibody levels, we found
no differences in pre-immunization PPS-specific IgM, IgG or OPA between groups.
Similar to the findings described by Crum-Cianflone et al,21 we also did not find significant
differences between AA and Caucasian HIV-positive groups in post-immunization PPSspecific IgG levels against all serotypes measured (Figure 3.1).
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In contrast, we found significant differences in the functional antibody response between
the AA and Caucasian populations post-immunization with the polysaccharide vaccine in
the response to 2 of the 3 serotypes tested, namely 14 and 19A. Prior immunization with
the conjugate vaccine was able to overcome the difference between ethnicities in the case
of serotype 19A but not in the response to serotype 14. This may be attributed to the small
group size of the Caucasian group immunized with PCV/PPV (n=8), and relative low OPA
titers in response to PPS 19A as compared to serotype 14 for PCV/PPV vaccination
regimen.
Several investigators have noted a poor correlation between quantitative antibody
response as measured by ELISA and opsonophagocytic activity.28,32,33 Therefore,
individuals with antibody levels thought to be commensurate with protection, may not
necessarily be protected against disease. Reduced or absent antibody activity, as
determined by opsonophagocytic assay could be related to race-related distinctions in prevaccination gene expression levels in IgM memory B cells. Studies have shown, that IgM
memory B cells is a predominant population of PPS-responding B cells, regardless of
vaccination regimen in both healthy adults and HIV-positive individuals 34 and that absence
of IgM memory B cells leads to high susceptibility to bacterial infection and inability to
respond to polysaccharide antigens as seen in newborns, asplenic or splenectomized
individuals, and patients with immune deficiencies. 35,36,37 In agreement with other studies,
we demonstrated significantly different profiles of gene expression between African
American and Caucasian ethnic groups.38 We observed higher levels of expression in 33
genes on the single cell level in AA as compared to Caucasian which could in part influence
immune response to pneumococcal vaccination. Despite the fact, that some genes are
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expressed more in AA group, only the Caucasian group demonstrated superior immune
response as determined by OPA to PPS 14 and PPS19A. This could be attributed to more
frequently observed bimodality within the single B cell population in AA which suggests
that there is a greater variation in levels of gene expression between individual cells in AA
as compared to Caucasian group and therefore in part explains lower functional antibody
activity and more notable discrepancies between serum antibody and opsonophagocytic
titers produced
It has been postulated that increased levels of inflammation may lead to poorly
functional antibody responses. Poor immune response to influenza vaccination was found
to correlate with increased inflammation in the elderly population.39,40 We measured 10
inflammatory markers in the pre-immune serum of all study participants and found no
difference in any of the markers between study groups. These results suggest that factors
other than inflammation are responsible for the inter racial differences in functional
antibody activity. It is important to mention however, that we specifically studied a cohort
of HIV+ individuals with well controlled disease (at least 1 year on antiretroviral therapy
and suppressed viral loads) without concurrent HIV-related co-infections. The fact that the
disease is well-controlled could have impacted the detection of any possible differences in
the expression of inflammatory markers and racial differences. A cohort of individuals with
high viral loads and very low CD4 counts might display different pre-immunization
inflammatory states and racial differences.
In conclusion, in this small but uniform cohort of HIV positive Caucasian and AA
individuals between 40-65 years of age, we made some unique observations. First, as in
previous studies, we found no significant differences in IgG or IgM antibody responses
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between Caucasian and AA participants in the immune response to immunization with
either PPV or PCV/PPV only. However, when we measured opsonophagocytic activity,
likely more reflective of protective immunity, we found significant differences between
races in response to 2 of 3 serotypes measured. Furthermore, we demonstrated that gene
expression levels between single cell IgM memory B cell populations are significantly
different between ethnicities that might be a contributing factor to differences in immune
response to pneumococcal antigens.
Our study has several limitations. Although, we are reporting the immune response
to 3 serotypes, the results are significant. The serotypes evaluated in this study are diverse
and elicit different levels of immune response and therefore provide a template of possible
behavior in response to other serotypes. Furthermore, our results demonstrated that there
was a significant difference in geometric mean antibody titers (GMT) between AfricanAmericans and Caucasians for serotypes 14 and 19A, however we have not tested if a) our
results will hold up in a larger future study, and show that African-Americans truly have a
lower average GMT or b) African Americans have a subgroup that has a lower GMT and
a subgroup that may be similar to Caucasian population. At this point, our study supports
the existence of a subgroup of African Americans that has lower GMT and, in this
subgroup, lower OPA titers corresponded to lower anti-PPS IgG antibody concentrations.
The subgroup of African Americans with higher OPA titers consistently had higher antiPPS IgG antibody concentrations
Our future studies will focus on mechanistic aspects of the immune response which
will include characterization of polysaccharide-specific B cells and identification of
variations in intercellular gene expression that shapes polysaccharide-specific B cell
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responses in different ethnic groups. These studies will significantly increase our
knowledge of the genetic identities of B cells in HIV+ individuals of African American
and Caucasian ethnicities and help to uncover B cell complexity and diversity. We will
gain new insights into mechanisms underlying B cell dysfunction phenotype in HIV+
individuals that leads to poor responses to pneumococcal vaccination.
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Chapter 4
Impact of inflammation on immune responses to pneumococcal vaccination
4.1.Introduction
Inflammation plays a protective role in stimulating immunological responses to
infectious agents and injury, however it can also contribute to the pathophysiology of
chronic diseases.1The normal aging process is characterized by dysregulation of antiinflammatory and pro-inflammatory networks, which together result in a low-grade
chronic inflammation status termed inflammaging. Inflammaging is characterized by an
increase in circulating cytokines and acute phase proteins, which together lead to
alterations in immune response to antigens.1,2,3 Pro-inflammatory cytokines such as IL-6,
TNF-α, and IL-1β are some of the major contributors to inflammaging in healthy elderly
individuals.4 Interestingly, the same features of chronic inflammation are present in
individuals with HIV who are decades younger.5
Studies have shown that high levels of pro-inflammatory cytokines are associated
with impaired vaccine responses. Indeed, elevated levels of TNF-α in the elderly were
linked to a reduced influenza vaccine response.6 Similarly, in post-menopausal HIV+
women, plasma levels of TNF- α inversely correlated with the antibody response to the
influenza vaccine.7 However, the relevance of high levels of TNF-α and other
inflammatory cytokines to pneumococcal vaccine responses have not been elucidated.8,9 In
this study we investigated if the degree of immune activation and/or inflammation has an
effect on immune responses to pneumococcal vaccination by measuring serum levels of
pro- and anti-inflammatory molecules in aging HIV+ individuals as compared to aging
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HIV- individuals and correlating these with the post-immunization opsonophagocytic
response.
4.2.Methods
Inflammatory marker analysis
Pre-immunization serum (Day 0) was analyzed using Custom Human
Cytokine/Chemokine P4 2-Plex Assay (Eve Technologies, Calgary, Canada). This
cytokine array (based on Luminex’s xMAP technology, Austin, TX) allows quantification
of 10 pro-inflammatory and anti-inflammatory cytokines and chemokines: IL-1B, IL-1Ra,
IL-6, IL-8, IL-10, IP-10, TNF-α, sCD-40, BAFF, and APRIL. Experimental procedures
were carried according to manufacturer’s protocol (Eve Technologies, Calgary, Canada).
Statistical Analysis
Serum cytokines and chemokines were reported in pg/ml or ng/ml. The differences
between the groups were calculated using nonpaired Mann-Whitney t-test. Correlation
between OPA titers (reported in chapter 2) and inflammatory markers were determined by
Pearson’s correlation coefficient. P-values < 0.05 were considered significant.
4.3.Results
Inflammatory profiles
We found significant differences in inflammatory profiles at baseline (Day 0)
between aging HIV+ and aging HIV- negative study participants. Aging HIV+ individuals
had significantly higher levels of expression of proinflammatory cytokines: IP-10 (pvalue=0.0002), sCD40L (p-value=0.01), TNF-α (p-value=0.003) as well as higher levels
of APRIL (p=0.0025). There were no significant differences in the expression levels of
anti-inflammatory cytokines between aging HIV+ and aging HIV-. (Figure 4.1.)
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Correlation between inflammatory markers and OPA
We found that there was a significant correlation (r=0.8, p=0.001) between
expression of IP-10 and functional antibody response to PPS23F but not to PPS14 in aging
HIV+ individuals. There were no correlations between other inflammatory markers
examined at baseline and immune responses to pneumococcal vaccination as measured by
OPA to serotypes 14 and 23F in aging HIV+ and aging HIV- individuals (Figure 4.2-4.3).
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Figure 4. 1. Serum cytokines and chemokines levels. Serum levels of pro-inflammatory
markers: IL-1β, IL-6, IL-8, IP-10, sCD40L, TNF-α, anti-inflammatory: IL-1RA, IL-10 as
well as BAFF and APRIL were measured using Luminex assay in HIV-positive and HIVnegative individuals prior to immunization. Difference between the groups were compared
using unpaired Mann-Whitney test; p-values< 0.05 were considered significant.
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Figure 4. 2. Correlation between post-vaccination OPA titers to PPS14 and
inflammatory markers.
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Figure 4. 3. Correlation between post-vaccination OPA titers to PPS23F and
inflammatory markers.
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4.4.Discussion
To elucidate factors contributing to poor immune response to pneumococcal
vaccination, we investigated the relationship between functional antibody response and the
expression levels of pro-inflammatory markers: IL-1β, IL-6, IL-8, IP-10, sCD40L, TNFα, anti-inflammatory: IL-1RA, IL-10 as well as BAFF and APRIL. In a sample
representative of aging HIV+ and aging HIV- population, we found that the expression
levels of IP-10 correlated with functional antibody response to serotype 23F only in aging
HIV+ individuals. However, no other correlations between other inflammatory markers
measured and responses to pneumococcal vaccine were found for either group.
To probe the mechanisms of impaired vaccine responses, we examined the
expression of TNF family of molecules BAFF (B cell activating factor) and APRIL (a
proliferation-inducing ligand) in aging HIV+ and aging HIV- groups. BAFF and APRIL
are important mediators of T cell-independent immune responses and play a role in class
switch recombination, B cell differentiation and survival.6,10 Together these factors
function to regulate antibody responses. In this study we show, that aging HIV+ individuals
had significantly higher levels of APRIL but not BAFF as compared to aging HIV- persons.
APRIL mediates a stimulatory signal to B cells during TI-2 humoral response by
interacting with TACI or BCMA which leads to the production of IgG and IgM antibodies.
Studies have shown that TACI deficient mice (TACI-/-) do not respond to TI-2 immune
responses, therefore, APRIL/TACI axis are important players in generating response to
polysaccharide antigens. Elevated levels of APRIL result in the production of high levels
of IgM and IgG, despite this, our data suggest that in aging HIV+ persons this does not
result in improved immune response to pneumococcal vaccination (chapter 2, figure 2-3);
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furthermore, there was no correlation between APRIL levels and functional antibody
response.11,12,13 One of the possible explanations is diminished levels of TACI. Our
previous studies have shown, that HIV-positive and HIV-negative individuals have similar
surface TACI expression, however serum TACI levels are significantly lower in HIV+.14
It is speculated that BCR recognition of antigens result in cleavage of surface TACI from
activated B cells to a lower extent in HIV+ individuals as compared to HIV-negative
individuals, resulting in diminished Ig secretion.14
The CD40 ligand/CD40 pathway plays a significant role in immune regulation by
initiating and advancing both cellular and humoral immune responses.15 CD40/CD40L
interaction is required for B-cell activation, class switching, and antibody production. A
soluble isoform of CD40L (sCD40L), formed by cleaving a surface molecule expressed on
activated T cells, is able to function similarly to T-cell derived CD40L.16 Studies have
shown that sCD40L can be detected in healthy individuals at low levels, however in
patients with chronic inflammation including systemic lupus erythematosus (SLE),
rheumatoid arthritis, systemic vasculitis, and lymphoproliferative disorders sCD40L is
elevated. 17,18,19 In line with other studies, we show that aging HIV+ individuals have higher
levels of sCD40L as compared to aging HIV- persons, however, there was no correlation
found between overexpression of sCD40L and functional antibody response to
pneumococcal vaccination.16 It is possible that high levels of sCD40L can be one of the
contributing factors of B cell impairment and chronic activation in HIV+ adults but the
mechanisms are yet to be determined.20
Another member of TNF family, TNF-α was also examined. TNF-α, is a proinflammatory cytokine that can positively or negatively modulate immune responses and
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can have an impact on vaccine immunity.21 High levels of serum TNF-α in the elderly was
associated with diminished influenza vaccine response. Elevated levels of TNF-α in HIV+
individuals have also been previously reported.22 We examined the relevance of TNF-α to
pneumococcal vaccine. However, found no correlation with functional antibody levels.
To further understand the role of inflammatory markers that contribute towards
diminished pneumococcal vaccine responses in high risk groups, we examined serum
levels of the following inflammatory cytokines: IL-1B, IL-6, IL-8 and anti-inflammatory
cytokines:IL-1RA, IL-10. However, we have not found any significant correlation between
expression of these cytokines and functional antibody responses to pneumococcal
vaccination in aging HIV+ and aging HIV- persons.
Finally, we examined the role of IP-10. IP-10 (CXCL10) is a proinflammatory
cytokine induced in response to IFN-γ. It is produced by a variety of cell types, including
leukocytes, monocyte, and endothelial cells and can modulate innate and adaptive immune
responses.23 Elevated levels of IP-10 have been associated with a number of inflammatory
conditions including HIV infection. Similarly to others, we show that aging HIV+
individuals have significantly higher levels of IP-10 at baseline.23,24 We further
demonstrate that elevated levels of IP-10 correlated with functional antibody response to
serotype 23F in aging HIV+ group. In humans, macrophage derived IP-10 has been
reported to be involved in plasma cell (PC) development including proliferation, class
switching, and terminal differentiation. It functions through the amplification loop where
B cell derived IL-6 induces macrophages to produce IP-10, which in turn induces the B
cell autocrine secretion of IL-6 and leads to PC differentiation.25 This mechanism is highly
dependent on signal transducer and activator of transcription factor 3 (STAT3)
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phosphorylation.26 Studies have shown that STAT3 is required to generate the memory B
cell pool and is indispensable for B cell differentiation of IgM, IgG, and IgA secreting PCs
as well as adequate response to TI-2 antigens.27 It is speculated that due to elevated levels
of IP-10, there is a dysregulation of STAT3 function which negatively affects immune
response to pneumococcal vaccine. However, it remains to be elucidated.28
In conclusion, our study demonstrates that: 1) aging HIV+ individuals have a
distinct profile of inflammatory markers with increased IP-10, sCD40L, TNF-α, APRIL as
compared to aging HIV- individuals; 2) IP-10 expression correlates with functional
antibody response to serotype 23F but not to serotype 14 in aging HIV+ individuals; 3)
inflammatory markers did not correlate with immune response to pneumococcal vaccine
and immune activation in aging HIV- individuals, suggesting that pneumococcal vaccine
responses are not always influenced by generalized inflammatory status and perhaps is
impacted by low OPA. The limitations of this study include small sample size, limited
number of inflammatory markers tested, and limited number of serotypes evaluated. Future
studies will involve phenotypic profiling of polysaccharide specific B cells in order to
identify potential mechanisms and further involvement of IP-10 that potentially govern
poor response to pneumococcal vaccination in high risk population such as aging and
HIV+.
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Chapter 5
Phenotypic characteristics of human IgM memory B cells in immune response to
pneumococcal vaccination in aging HIV+ individuals
5.1. Introduction
The nature and phenotype of the B cells that respond to pneumococcal
polysaccharide is a point of discussion. It has been suggested that IgM memory B cells are
indispensable for the production of anti-polysaccharide antibodies.13,14,15,16 In support of
this concept, it has been demonstrated that individuals with diminished or absent IgM
memory B cells including persons with asplenia, whether congenital of acquired, patients
with common variable immunodeficiency (CVID) and infants under the age of two, all
share the same clinical features: increased susceptibility to infections caused by
encapsulated bacteria such as S. pneumoniae and impaired response to polysaccharide
vaccines.17,18 Therefore, the lack of IgM memory B cells, independent of cause of
depletion, is directly correlated with the inability to efficiently respond to pneumococcal
antigens.
The biology and nature of polysaccharide specific IgM memory B cells have not
been well characterized in either healthy or high-risk populations such as HIV+. This was
partly due to technical limitations and inability to correctly isolate PPS-specific B cells and
partly due to very low numbers of these cells present in the bloodstream postimmunization.19 It is estimated that post-immunization PPS-specific B cells represent
between 1-2.75% of total B cells in healthy individuals, and is significantly lower in the
elderly and aging HIV+. An accurate analysis requires screening of very large cell numbers
in order to isolate the relevant cell type.19,21 The analysis of non-specific IgM memory B
cells on the other hand, was limited to genetic profiling, which cannot distinguish the
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dynamics and distinct states within the cells, or to limited analysis of cell markers on a
small scale by using flow cytometry.22,23,24
We have developed and validated a PPS-specific staining method that allows
detection of fluorescently labeled PPS-specific B cells while preserving their functionality
and specificity.19 The use of this method minimizes the potential cross-reactivity with
linking agents and results in lower background binding and more accurate phenotypic
analysis using flow cytometry. This method enabled us to identify the phenotype of B cells
responding to PPV23 vaccine in healthy young adults. We found that the majority of preimmunization B cells are naïve CD27-IgM+ B cells, whereas almost 30 percent of B cells
are equally distributed between IgM memory B cells (CD27+IgM+) and switched memory
B cells (CD27+IgM-). In contrast, the analysis of post-immunization B cell population in
healthy young adults revealed that the predominant population of polysaccharide specific
B cells expresses IgM memory phenotype (IgM+CD27+).19 The number of IgM memory
B cells decreases significantly with age.8,20 When we analyzed the post-immunization
phenotype of PPS-specific B cells, we found an age-related decrease in percentage of IgM
memory B cells with a significant increase of PPS-specific switched memory B cells.
(Figure 5.1.) Unlike aging individuals, healthy young adults produce high levels of
functional antibodies in response to vaccine (Chapter 2, Figure 2.2) which further provides
support of the importance of IgM memory B cells in the response to pneumococcal
polysaccharides. It is speculated that healthy elderly at least partially, compensate the loss
of IgM memory B cells by responding to vaccination with PPS-specific switched memory
B cells. Although the decrease in absolute number of IgM memory B cells may in part be
responsible for the loss of functional antibody activity in the elderly, altered function of
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the aging IgM memory B cells may also play an important role. Collectively, these findings
warrant further investigation of IgM memory B cells in order to understand the mechanisms
of diminished immune responses that are seen in high risk groups such as the elderly and
HIV+.

Figure 5. 1. The phenotype of PPS-specific B cells changes with age in healthy
individuals. The phenotypes of B lymphocytes responding to pneumococcal vaccination
were determined by flow cytometry. P-values <0.05 were considered significant. *p<0.05,
**<0.01, ***p<0.001

In this study, we investigated the effect of HIV infection and aging on B cell
immunity in well-controlled young and aging HIV+ persons on long term ART with CD4
counts above 200 and undetectable HIV viral loads. We characterized the phenotype of the
IgM memory B cells and polysaccharide specific IgM memory B cells, individual cellular
changes within these populations and identified variations in inter-cellular gene expression
on a single cell levels that shape polysaccharide–specific B cell responses.

75

5.2. Methods
Flow cytometry and cell sorting
Peripheral blood mononuclear cells (PBMCs) were collected from HIV+ and HIVstudy volunteers either on day 0 (pre-immunization) or day 7 (post-immunization with
PPV23). Lymphocytes were separated using Ficoll Hypaque method and stained with
fluorochrome-conjugated monoclonal antibodies using the following anti-human
antigens:CD19 (APC-Cy), CD27 (PerCP-Cy5.5), and IgM (APC); for post-immunization
samples the cells were also labeled with fluorescently conjugated pneumococcal PPS14 (5DTAF) or PPS23F (5-DTAF) for analysis of polysaccharide specific B cells as previously
described.19 Additionally cells were stained with LIVE/DEAD Blue fluorescent reactive
dye in order to exclude dead cells from the analysis. IgM memory B cells
(CD19+CD27+IgM+) were sorted using Beckman MoFLo Astrious sorter based on the
gating strategy described in Figure 2. Analysis was performed using FlowJo software.
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Figure 5. 2. Schematic representation of gating strategies to analyze and sort IgM
memory B cells (CD27+IgM+) on day 0 (pre-immunization) and PPS-specific IgM
memory B cells (PPS+CD27+IgM+) on day 7 (post-immunization with PPV23).
Lymphocytes were stained with fluorescently labeled antibodies and PPS (postimmunization analysis) for phenotypic characterization. Lymphocytes were gated to
exclude doublet before identifying CD19+ B cells. For pre-immunization evaluation,
CD19+ B cells were further identified based on the expression of both CD27 and IgM
(CD19+CD27+IgM+); for day 7 post-immunization, lymphocytes were selected based on
the expression of PPS14 and further selected based on double positive expression of CD27
and IgM. All flow cytometry gates were plotted using fluorescent minus one controls
(FMO).
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Single cell assays
1621 Cells used for pre-immunization single cell RT PCR analysis were isolated
and sorted from 17 donors: 4 young HIV- individuals, 5 aging HIV- individuals, 5 young
HIV+ individuals, 3 aging HIV+ individuals. 263 Cells used for post-immunization single
cell RT PCR were isolated from 4 donors: 1 young HIV-, 1 aging HIV+, 1 young HIV+,
and 1 aging HIV+.
cDNA. Single cell gene expression experiments were performed using Fluidigm
96.96 qPCR Dynamic array integrated fluidic circuits (IFCs) and HD Biomark Instrument
on sorted IgM memory B cells (CD19+CD27+IgM+). C1 Single Cell Auto Prep System
was used to capture single cells and perform targeted pre-amplification utilizing C1
Integrated fluidic circuits (IFCs). Briefly, following IFCs priming cell mixture was
resuspended in Suspension reagent (Fluidigm) at a concentration of 40,000 cells per 100
ul and loaded into IFC. Next, cells were imaged to ensure proper capture. Cell lysing,
reverse transcription, preamplification and harvesting the amplified products was
performed according to Fluidigm’s recommended protocol (PN 100-4904 L1).
Gene expression analysis. A PCR master mix containing both EvaGreen and ROX
was used; primers were designed using D3 assay design specific for genes involved in TI2 responses ( BAFF-R, TACI, BCMA, CD80, CD86, CD40, CD21, TLR9, AICD, TCF3),
apoptosis (Bcl-2, Bcl-XL, Mcl-1, BAX, BAD, BIM, FAS, BIK, TNSF15, Siva1), cytokines
and receptors (IL-1β, IL-4, IL-6, IL-7, IL-8, IL-10, IFNGR, IFN-γ, TNF-α, TLR1, TLR2,
TLR4, CCR2, CXCL8), transcription factors ( IRF4, BACH2, PRDM1, XBP1, Bcl6, Pax5, IKZF3, SPIB, FOXO1), lymphocyte signaling (CBLB, FCRL2, CD1D, CD200, LAIR1,
CD72, RFTN1, LCP2, GCSAM, NTE5, CD39, MS4A1, ENTPD1), metabolism (HKII,
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PFKP, ENO1, PGAM, LDHA, TYMS, CPT1, GPT2). Single cell qPCR was performed
according to Fluidigm’s recommended protocol (PN 100-9792 B1).
Statistical Analysis
Flow Cytometry: Different groups were compared using an unpaired t test. Pvalues <0.05 were considered statistically significant.
Single Cell RT PCR: This study examined single cell gene expression preimmunization at Day 0 (and in subset, day 7 post-immunization) in HIV- 21-40, HIV+ 2140, HIV- 50-65, and HIV+ 50-65 patients. In the preliminary analysis, 2 distinct cell types
were identified based on hierarchical clustering and thus one goal is to determine if there
is an association between different patient characteristics with cell type, differences in the
proportion of each cell type, and differences in single cell gene expression by cell or patient
type.
Thus, the main goals in this analysis were to (1) compare the proportion of each
cell type by HIV status and age group and (2) to look at gene expression between HIV/Age
groups within each cell type and compare within group between cell types. The data
included 1621 cells from 17 unique donors: 5 Older HIV- patients, 3 older HIV+ patients,
4 younger HIV- patients, and 4 younger HIV+ patients for pre-immunization analysis and
268 cells from 4 unique donors: 1 young HIV-, 1 young HIV+, 1 aging HIV- and 1 aging
HIV+ for post-immunization analysis. The association between cell type with HIV status
and age group was evaluated using a generalized estimating equation (GEE) approach
using cell type as the dependent variable, assuming a binary distribution and a logit link.
The model included fixed effects for age group, HIV status, and the interaction between
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age group and HIV status as well as a random subject effect to account for clustering within
patients.
We also examined differences in gene expression for the 65 genes considered in the
RT-qPCR analysis between HIV and age groups within the 2 cell populations as well as
differences within group between the two cell populations. Data were cleaned prior to
analysis using the Fluidigm SC work flow described in the Fluidigm Singular Analysis
Toolset User Guide. Cleaning the data included replacement of values the reported “No
Call” or “Fail” with 0, identifying outliers, and calculation of Log2Ex by subtracting the
observed Ct from 24- if this value was negative the Log2Ex was reported as 0 and otherwise
it was reported as 24 – Ct[Gene].
The association between gene expression with HIV status, age group, and cell type
was evaluated using a series of linear regression models. Differences between the groups
were evaluated based on contrasts from the linear model and differences considered in this
analysis included all pairwise comparisons by combinations of HIV status and Age within
cell type (12 comparisons) and pairwise comparisons by cell type within group (4
comparisons).

The p-values were adjusted using the Tukey’s Honestly significant

difference approach which is consistent with the Fluidigm SC R package.
5.3. Results
The phenotype of PPS-specific B cells.
Our previous studies showed that pre-immunization B cell phenotype distribution
in HIV+ consists predominantly of naïve B cells, with almost equal percentages of IgM
memory and switched memory B cells. In this study, we analyzed the post-immunization
phenotype in young HIV+ as compared to aging HIV+. The analysis of post-immunization
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PPS14 and PPS23 polysaccharide- specific B cells in young and aging HIV+ individuals
revealed there are no significant differences between young and aging HIV+ individuals
and there is no age-related shift in the phenotype of PPS-specific B cells in HIV+. (Figure
5.3).

Figure 5. 3. PPS-specific B cell phenotype post-immunization with pneumococcal
vaccination in young (21-40 years old) and aging (50-65 years old) HIV+ individuals.
The phenotypes of B lymphocytes responding to pneumococcal vaccination were
determined by flow cytometry. Significance was defined at p<0.05.

In HIV+ adults over the age of 50, the predominant response to pneumococcal
vaccination more closely resembled the response of healthy young adults, expressing the
IgM+CD27+ phenotype, albeit at significantly lower levels (Figure 5.4). It is important to
note, that both aging HIV- and aging HIV+ individuals demonstrated significantly lower
numbers of B cells (all phenotypes) compared to healthy young adults.
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Young HIV-

Aging HIV-

Aging HIV+

Figure 5. 4. Figure 5.4. Post-immunization PPS-specific B cells phenotype in young
adults, aging HIV-, and aging HIV+. P-values <0.05 were considered significant.
*p<0.05, **<0.01, ***p<0.001

Single cell gene expression profiling revealed heterogeneity within preimmunization human IgM memory B cell population. Hierarchical clustering analysis
of gene expression showed that there is a segregation of IgM memory B cell population
into two subpopulations. These two subpopulations are distinct and present in all four study
groups (young HIV- and HIV+ as well as aging HIV- and HIV+).
Proportion of Subpopulations by Group: There was a significant difference in the
ratio of IgM memory B cells belonging to Subpopulation 2 versus Subpopulation 1 between
young HIV+ patients and aging HIV+ patients (p = 0.010) with young HIV+ patients
having a significantly higher percentage of cells in Subpopulation 2. No other differences
noted between the groups, in terms of the proportion of cells in Subpopulation 1 versus 2.
The frequency of subpopulation 1 was 56% in young HIV-, 39% in young HIV+, 27% in
aging HIV-, and 68% in aging HIV+. The absolute number of IgM memory B cells was
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significantly lower (p<0.05) in aging HIV+ individuals as compared to healthy young
adults. (Figure 5.5 B, C).
Gene Expression results subpopulation 1 vs subpopulation 2: For this analysis, we
focused on genes involved in T cell independent immune responses which included CD40,
TLR9, BCMA, CD86, AICDA, CD21, CD80, TACI, TCF3, and BAFF-R. (Figures 5.5,
5.6, and 5.7). We found significant differences in gene expression levels in members of
BAFF/APRIL family between Subpopulation 1 and Subpopulation 2. Levels of BAFF-R
were significantly higher in Subpopulation 1 in young HIV- (p<0.0001), aging HIV(p<0.0001), young HIV+(p<0.0001), and aging HIV+ (p<0.0001) as compared to
Subpopulation 2. Similarly, TACI levels were significantly higher in Subpopulation 1 in
all groups examined (young HIV- p<0.0001, young HIV+ p<0.0001, aging HIV- p<0.0001,
aging HIV+ p<0.0001). BCMA however, was similarly expressed between subpopulations
in young HIV+ group but was significantly higher in young HIV-(p<0.0001), aging HIV(p=0.008) and HIV+ (p=0.001) in Subpopulation 1 as compared to Subpopulation 2. We
also assessed expression levels of co-stimulatory molecules CD80, CD86, and CD40. We
found that levels of CD80 were higher in subpopulation 1 as compared to subpopulation 2
in young HIV+ (p<0.0001), aging HIV-(p<0.0001), and aging HIV+ (0.0001) but not in
young HIV-. There were no differences in expression of CD86 and CD40 between
Subpopulation 1 and Subpopulation 2 in young and aging HIV+ as well as aging HIVgroup. However, we found significant differences in young HIV- group; levels of CD86
and CD40 were significantly lower in Subpopulation 1 as compared to Subpopulation 2
(p<0.0001, p<0.0001 respectively). TCF3 was significantly higher in Subpopulation 1
versus Subpopulation 2 in all groups. There was no difference detected in TLR9 or AICDA
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between subpopulations or groups while AICDA expression between subpopulations
differed only in aging HIV+.
Significant differences between subpopulation 1 and subpopulation 2 were also
noted for other genes including metabolic genes such as CPT1A, GPT2, genes that play a
role in signaling MS4A1, FCRL2 as well transcription factors IRF4, IKZF3 to name the
few.
Gene expression in Subpopulation 1: Within subpopulation 1 there were no
differences between groups in expression of BAFF-R and TACI. However, there was a
significant difference in expression of BCMA between young HIV+ and aging HIV+
(p=0.02). When we examined the differences in CD80 expression between the study groups
within Subpopulation 1, we found that it was significantly higher in young HIV+
(p<0.0001), aging HIV- (p=0.004), and aging HIV+ (p<0.0001) as compared to young
HIV- group. Similarly, we found that the levels of CD86 were significantly higher in young
HIV+ (p<0.0001), aging HIV-(p<0.0001), and aging HIV+ (p<0.0001) in subpopulation 1
as compared to young HIV- and levels of CD40 were higher as well (p<0.0001, p<0.0001,
p<0.0001 respectively). Overall, CD40, CD80, and CD86 in Subpopulation 1, showed
lowest expression in young HIV- compared to all other groups.
Gene Expression in Subpopulation 2: We detected significant differences of
expression of TACI between young and aging HIV+ groups (p=0.0016). BAFF-R
expression was also significantly higher in young HIV+ and both aging HIV- and HIV+.
There were no differences in the expression of CD80, AICDA, and TLR9 between any of
the groups in Subpopulation 2.
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Figure 5. 5. Single cell RT PCR heatmap depicting 2 distinct subpopulations present
within sorted IgM memory B cells in young HIV-, young HIV+, aging HIV-, and aging
HIV+ groups. A)1621 Cells used for pre-immunization single cell RT PCR analysis were
isolated and sorted from 17 donors: 4 young HIV- individuals, 5 aging HIV- individuals,
5 young HIV+ individuals, 3 aging HIV+ individuals. Single cell RT PCR was performed
on cells isolated from each donor individually. B) Subpopulation 1 and 2 distribution in all
study groups. C) Absolute number of IgM memory B cells in study groups. P-values <0.05
were considered significant. *p<0.05, **<0.01, ***p<0.001
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Figure 5. 6. Expression levels of BAFF-R, TACI, and BCMA in subpopulation 1 as
compared to subpopulation 2 in young HIV-, young HIV+, aging HIV-, and aging
HIV+ groups in non-specific IgM memory B cells. The association between gene
expression with HIV status, age group, and cell type was evaluated using a series of linear
regression models. The p-values were adjusted using the Tukey’s Honestly significant
difference approach which is consistent with the Fluidigm SC R package. P-values <0.05
were considered significant. *p<0.05, **<0.01, ***p<0.001
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Figure 5. 7. Expression levels of CD80, CD86, and CD40 in in subpopulation 1 as
compared to subpopulation 2 in young HIV-, young HIV+, aging HIV-, and aging
HIV+ groups in non-specific IgM memory B cells. The association between gene
expression with HIV status, age group, and cell type was evaluated using a series of linear
regression models. The p-values were adjusted using the Tukey’s Honestly significant
difference approach which is consistent with the Fluidigm SC R package. P-values <0.05
were considered significant. *p<0.05, **<0.01, ***p<0.001
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Figure 5. 8. Expression levels of TCF3, AICDA, and TLR9 in in subpopulation 1 as
compared to subpopulation 2 in young HIV-, young HIV+, aging HIV-, and aging
HIV+ groups in non-specific IgM memory B cells. The association between gene
expression with HIV status, age group, and cell type was evaluated using a series of linear
regression models. The p-values were adjusted using the Tukey’s Honestly significant
difference approach which is consistent with the Fluidigm SC R package. P-values <0.05
were considered significant. *p<0.05, **<0.01, ***p<0.001
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Single cell gene expression profiling of PPS14-specific IgM memory B cells
post-immunization demonstrates heterogeneity of single IgM memory B cells.
Hierarchical clustering analysis of gene expression levels in polysaccharide specific IgM
memory B cells demonstrated similar segregation into two subpopulations that was
observed in IgM memory B cells analyzed pre-immunization. These two subpopulations
were observed in all study groups. (Figure 5.9).
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Figure 5. 9. Single cell RT PCR
heatmap depicting 2 distinct
subpopulations present within
YOUNG HIV- YOUNG AGING HIV- AGING HIV+
sorted
polysaccharide-specific
HIV+
IgM memory B cells in young
HIV-, young HIV+, aging HIV-,
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and aging HIV+ groups. A) 268
cells used for pre-immunization
single cell RT PCR analysis were isolated and sorted from 4 donors: 1 young HIVindividuals, 1 aging HIV- individuals, 1 young HIV+ individuals, 1 aging HIV+
individuals. Single cell RT PCR was performed on cells isolated from each donor
individually. B) Subpopulation 1 and 2 distribution in all study groups.
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Proportion of Subpopulations by Group: The frequency of subpopulation 1 was
58% in young HIV-, 63% in young HIV+, 68% in aging HIV-, and 54% in aging HIV-.
Gene Expression results subpopulation 1 vs subpopulation 2: Similar to the
analysis of pre-immunization IgM memory B cells, we focused on genes involved in T cell
independent immune responses which included CD40, TLR9, BCMA, CD86, AICDA,
CD21, CD80, TACI, TCF3, and BAFF-R as well (Figures 5.10, 5.11,5.12). We found that
the levels of expression of BAFF-R were significantly higher in subpopulation 1 as
compared to subpopulation 2 in young HIV- (p<0.0001), young HIV+ (p<0.0001), aging
HIV- (p<0.0001); the levels of BAFF-R in subpopulation 1 appeared to be higher in aging
HIV+ group, however these differences did not reach statistical significance. TACI levels
were also significantly higher in subpopulation 1 in young HIV- group (p<0.0001) and
aging HIV- group (p<0.0001) as compared to subpopulation 2. Levels of BCMA were
significantly higher in young HIV- (p=0.04) and aging HIV+ (p=0.0002) in subpopulation
1 as compared to subpopulation 2. We also assessed co-stimulatory molecules in such
CD80/86 and CD40. We found that CD80 was significantly higher in subpopulation 1 in
all groups however, it reached statistical significance only in aging HIV+ group
(p<0.0001). Similarly, CD86 and CD40 were significantly higher in aging HIV+ group in
subpopulation 1 (p<0.0001, p<0.0001 respectively).
Significant differences between subpopulation 1 and subpopulation 2 were also
observed for other genes including transcription factors IKZF3, PAX5, IRF4, metabolic
genes LDHA and other.
Gene expression within Subpopulation 1: We assessed gene expression levels
within subpopulations and found that there were significant differences in expression levels
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of BAFF-R between young HIV- and aging HIV+ groups (p<0.0001) and between aging
HIV- and aging HIV+ group (p<0.0001) in subpopulation 1. TACI expression levels were
significantly higher in aging HIV+ (p<0.0001) as compared to aging HIV- group, and as
compared to young HIV+ group (p<0.0001) in subpopulation 1. Similarly, levels of BCMA
were significantly higher in aging HIV+ as compared to aging HIV- (p<0.0001) and as
compared to young HIV+ (p<0.0001).
We found significant differences in levels of expression of CD80 and CD86. CD80
was significantly higher in young HIV- groups as compared to the aging HIV- group
(p=0.01), whereas it was significantly higher in aging HIV+ groups as compared to aging
HIV- group (p=0.01) and young HIV+ group (p=0.0001). Similarly, CD86 was
significantly higher in young HIV- as compared to young HIV+ (p=0.01), but higher in
aging HIV+ (p=0.0004); aging HIV+ group also demonstrated higher levels of CD86 as
compared to young HIV+ (p=0.04). Levels of AICDA were significantly higher in young
HIV- individuals as compared to aging HIV- (p<0.0001) and aging HIV+ (p<0.0001).
Levels of TCF3 and TLR9 were significantly different between the groups in
subpopulation 1.
Gene expression within Subpopulation 2: There were also differences in BAFF-R
between young HIV- and aging HIV+ (p=0.04), young HIV+ and aging HIV- (p=0.02),
and young HIV+ and aging HIV+ (p=0.01) in subpopulation 2. No differences between the
groups were detected for CD80, BCMA, CD86, TCF3, CD21. Levels of expression of
AICDA were significantly higher in young HIV- individual as compared to aging HIV(p<0.001), aging HIV+ (p<0.0001); young HIV+ groups had also higher levels of AICDA
as compared to aging HIV+ (p<0.0001).
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Figure 5. 10. Expression levels of BAFF-R, TACI, and BCMA in subpopulation 1 as
compared to subpopulation 2 in young HIV-, young HIV+, aging HIV-, and aging
HIV+ groups in PPS-specific IgM memory B cells. The association between gene
expression with HIV status, age group, and cell type was evaluated using a series of linear
regression models. The p-values were adjusted using the Tukey’s Honestly significant
difference approach which is consistent with the Fluidigm SC R package. P-values <0.05
were considered significant. *p<0.05, **<0.01, ***p<0.001
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Figure 5. 11. Expression levels of CD80, CD86, and CD40 in in subpopulation 1 as
compared to subpopulation 2 in young HIV-, young HIV+, aging HIV-, and aging
HIV+ groups in PPS-specific IgM memory B cells. The association between gene
expression with HIV status, age group, and cell type was evaluated using a series of linear
regression models. The p-values were adjusted using the Tukey’s Honestly significant
difference approach which is consistent with the Fluidigm SC R package. P-values <0.05
were considered significant. *p<0.05, **<0.01, ***p<0.001
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Figure 5. 12. Expression levels of TCF3, AICDA, and TLR9 in in subpopulation 1 as
compared to subpopulation 2 in young HIV-, young HIV+, aging HIV-, and aging
HIV+ groups in PPS-specific IgM memory B cells. The association between gene
expression with HIV status, age group, and cell type was evaluated using a series of linear
regression models. The p-values were adjusted using the Tukey’s Honestly significant
difference approach which is consistent with the Fluidigm SC R package. P-values <0.05
were considered significant. *p<0.05, **<0.01, ***p<0.001
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5.4. Discussion
In this study, we identified the phenotype of polysaccharide specific B cells in aging
HIV+ and aging HIV- groups and extensively characterized genetic signatures of IgM
memory B cells pre- and post-immunization on a single cell level. Our findings revealed
that in healthy individuals there is an age-related shift in the phenotype of PPS-specific B
cells from IgM memory in young adults to switched memory in aging persons. In contrast,
the analysis of PPS-specific B cells isolated from young and aging HIV+ individuals did
not demonstrate a similar age-related shift in B cell phenotype. Interestingly, aging HIV+
individuals phenotypically resembled young HIV- individuals. Both groups displayed
predominant PPS-specific IgM memory B cell phenotype albeit it was found less
frequently both in percentages and absolute numbers, in aging HIV+ individuals.
Despite the fact that young HIV- and aging HIV+ groups shared seemingly
homogeneous phenotype of PPS-specific IgM memory B cells but in different absolute
number, the functionality of these cells is different and results in contrasting ability to
produce functional antibody responses to pneumococcal vaccination. (Chapter 2, Fig.2.2).
We hypothesized that functional differences in IgM memory B cells are also driven by
heterogeneity present within the single cell population leading to skewed gene distribution
and resulting in fundamental differences in B cell function, in part responsible for impaired
vaccine responses in aging HIV+ persons. We approached this hypothesis by utilizing a
single cell RT PCR method which allowed us to perform unbiased characterization of IgM
memory B cells pre- and post-immunization.25 Unlike traditional approaches, using bulk
cell analysis and measuring combined responses to stimuli, single cell analysis allows to
dissect and understand immune responses to a greater extent. This becomes apparently
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important in the case of phenotypically similar but functionally different cells such as IgM
memory B cells in aging HIV+ individuals where a fraction of the cell population can be
potentially dysfunctional or dysregulated and bulk analysis fails to recognize these
changes.26 Furthermore, recent studies have shown that immune cell types that are
traditionally defined by a specific set of markers, can in fact, consist of different subtypes
that share overlapping signatures.27,28,29 For example, studies done by Gaublomme et al
demonstrated a great degree of heterogeneity in traditionally defined Th17 cell type; as a
result, these cells can display either pathogenic or regulatory functions.27 Another study by
Keren-Shaul et al led to identification of a novel and a very rare cell subpopulation of
microglia that has a potential to limit neurodegeneration in Alzheimer’s disease. This
discovery became possible only due to the advantages of the single cell approach.30
Collectively, these findings demonstrate that single cell methods allow to not only
characterize a spectrum of functional cell states that shape immune function and plasticity
within a cell population but also to distinguish rare cell types.
Using single cell approach, we were able to delineate the heterogeneity of human
IgM memory B cells by investigating 65 genes, mainly involved in the regulation of B cell
function and differentiation. We analyzed 1621 single IgM memory B cells isolated from
17 donors: 4 young HIV- individuals, 5 aging HIV- individuals, 5 young HIV+ individuals,
3 aging HIV+ individuals pre-immunization and 268 single PPS14 specific IgM memory
B cells post-immunization isolated from 4 unique donors: 1 young HIV-, 1 young HIV+,
1 aging HIV-, and 1 aging HIV+.
Analysis of IgM memory B cells obtained pre-immunization revealed the extensive
heterogeneity that exists within a seemingly homogeneous population. Hierarchical
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clustering analysis revealed that IgM memory B cells clustered into separate branches of
the dendrogram and identified two distinct subpopulations (subpopulation 1 and
subpopulation 2) with unique phenotypic characteristics that were present in healthy young
and aging individuals as well as in HIV+ young and aging persons. To understand the
significance of these findings and how presence of these subpopulation potentially
contributes to impaired vaccine responses in high risk groups such as the elderly and HIV+,
we analyzed expression levels of the genes directly or indirectly involved in responses to
polysaccharide antigens in these subpopulations. We found that these genes at the single
cell level demonstrated a highly multifaceted expression patterns that could not be detected
by bulk cell analysis.
Subpopulation 1 pre-immunization was characterized by significantly higher levels
of expression of BAFF-R and TACI in all study groups as compared to subpopulation 2.
This suggests that subpopulation 1 is more likely to dominate in T cell independent (TI-2)
immune response and therefore from here on will be the focus of the discussion.
BAFF-R and TACI are receptors that bind to two ligands: B cell activating factor
of the tumor necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL).
The interaction of these ligands with BAFF-R and TACI on B cells are critical for B cell
function and homeostasis. It also plays an important role in producing responses to TI-2
antigens and regulating antibody production.31,32,33,34 TI-2 antigens such as pneumococcal
polysaccharides stimulate immune response by cross-linking the B cell receptors (BCR)
and engaging TACI via BAFF or APRIL. This leads to an increase in transcript levels of
activation-induced cytidine deaminase (AID) and results in polysaccharide specific
antibody isotype switching and plasma cell production.31,35 Similarly, upon BCR
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crosslinking, BAFF-R engages BAFF leading to increased levels of prosurvival molecules
such as Bcl-2 and Bcl-x which results in enhanced secretion of both isotypes switched and
unswitched antibodies.31
TACI upregulation is suggested to augment antibody production in response to TI2 antigens and to facilitate the ability of B cells to become more reactive to BAFF and
APRIL. Absence or downregulation of TACI leads to unresponsiveness to TI-2
antigens.31,36,37,38 Chinen et al demonstrated that low levels of TACI expression directly
correlated with low levels of antigen specific antibodies produced in response to
pneumococcal polysaccharide vaccine in patients with CVID.39 These findings are in line
with our previous reports that levels of TACI are increased on antigen-specific B cells post
pneumococcal immunization.38,40
Here, we report that there is a significant heterogeneity in expression levels of
TACI and BAFF-R within IgM memory B cells pre-immunization which could impact
vaccine induced antibody production. Interestingly, when we compared TACI and BAFFR levels within the subpopulation 1 between HIV+ and HIV- groups, we found no
significant differences. We speculate, that despite similarities between the groups, the
effects of TACI and BAFF-R could still play a role in impaired vaccine response in high
risk groups due to differences in absolute numbers of IgM memory B cells. HIV+ and the
elderly are reported to have significantly lower percentage of B cells as compared to
healthy young adults.41 Finally, it is important to mention that we also evaluated expression
levels of BCMA, a third receptor that belongs to APRIL and BAFF family. Despite the fact
that we saw significant differences in BCMA expression between the study groups, it has
been previously reported to be dispensable in TI-2 immune response.42
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Next, we examined the expression of co-stimulatory molecules including CD80
(B7-1), CD86 (B7-2), and CD40. The B7 family of molecules are a predominant cluster of
molecules expressed on the surface of antigen presenting cells including B cells. 43
We found, that there was a significant upregulation of CD80 in young and aging
HIV+ groups as well as aging HIV- group as compared to young HIV- group. Similarly,
CD86 and CD40 were also upregulated in all groups except young HIV-. Increased levels
of expression costimulatory molecules such as CD80/CD86 on B cell have been previously
reported in inflammatory diseases such as lupus erythematosus and also in HIV.44,45
However, here we demonstrate that CD80 and CD86 molecules are overexpressed only in
one subpopulation of IgM memory B cells. This is an important finding because
predominance of IgM memory B subpopulation with higher levels of expression of
costimulatory molecules such CD80/CD86 and CD40 could potentially result in modified
B cell function, reflect B cell hyperactivity and translate into impaired vaccine specific
responses in the elderly and HIV+.
We also examined expression levels of TCF3, a gene that encodes transcription
factors E12 and E47 that play an important role in B cell differentiation and regulation of
mature B cell function.20 We found that subpopulation 1 had significantly higher levels of
expression of TCF3 in all groups. Furthermore, we found that subpopulation 1 was
metabolically more active and had higher levels of expression of signaling genes. This
further demonstrates that subpopulation 1 might have functional advantages over
subpopulation 2 and future studies should aim at exploring the ability of this subpopulation
to respond to antigen stimulation.
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Phenotypic characterization of pre-immunization subpopulation 1 demonstrated
potential functional advantages in the ability to respond to TI-2 antigens. Based on this
observation, we hypothesized that aging HIV+ individuals have low frequencies of
subpopulation 1 pre-immunization which in turn can have an adverse effect on their ability
to respond to TI-2 antigens. We compared the distribution of IgM memory B cells and
found that in young HIV- group 56% of IgM memory B cells belonged to subpopulation 1
whereas in aging HIV+ group 68% of cells belonged to subpopulation 1. However, when
we determined the absolute number of IgM memory B cells present in all groups, we found
that aging HIV+ individuals have 3-fold lower number of IgM memory B cells.
Collectively, these findings suggest that aging HIV+ individuals despite having higher
prevalence of subpopulation 1, have low absolute numbers of IgM memory B cells likely
associated with diminished ability to produce functional pneumococcal antibodies.
Next, we examined polysaccharide specific IgM memory B cells from young and
aging HIV- and young and aging HIV+ individuals. Similar, to findings from single cell
analysis of pre-immunization IgM memory B cells, we found that there are two distinct
subpopulations in post-immunization PPS-specific IgM memory B cells: subpopulation 1
and subpopulation 2. Subpopulation 1 was the predominant subpopulation in all study
groups: 58% in young HIV-, 63% in young HIV+, 68% in aging HIV- and 54% in aging
HIV+. However, the absolute number of IgM memory B cells was the lowest in young
HIV+ and aging HIV+ groups. Post-immunization Subpopulation 1 demonstrated higher
levels of expression of BAFF-R and TACI and therefore will be the focus of the discussion.
Levels of both TACI and BAFF-R as well as levels of co-stimulatory molecules including
CD80/86 were higher in aging HIV+ group as compared to young HIV- group, however
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levels of AICDA were significantly lower. Interestingly, levels of AICDA were
significantly lower even in post-immunization subpopulation 2 in aging HIV+. This
suggests that following BCR crosslinking by polysaccharide both TACI and BAFF-R
become engaged by BAFF or APRIL, which normally results in activation of AID.
However, in aging HIV+ due to low levels of expression of AICDA, there appears to be an
impairment in induction of AID. AID is essential for generation of antibody memory, gene
class switch DNA recombination (CSR) and somatic hypermutation (SHM) and is tightly
regulated by AICDA.46 AID is expressed on activated B cells and can function as a
biomarker of the quality of antibodies produced in response to TI-2 stimuli.20 Defective or
abnormal AID leads to dysregulated B cell function which has been previously documented
in the elderly. 20,46
Taken together, we show that there might be potential benefits of rescuing levels of
AID in order to increase CSR and SHM which would result in more robust immune
response to pneumococcal vaccination in aging HIV+ individuals. Low levels of
expression of AICDA was observed in pre-immunization subpopulation 1 in aging HIV+
but not aging HIV- and post immunization subpopulation 1 and 2 in both aging HIV-, and
more extreme in aging HIV+ and therefore leads us to believe that it can be one of the
contributing factors that results in differences in functionality of phenotypically similar
(Figure 5.3) PPS-specific IgM memory B cells in aging HIV+ as compared to young HIVgroups.
Collectively, our assessment of human IgM memory B cells revealed that this cell
population is heterogeneous and characterized by transcriptionally and functionally
different subpopulations. This was confirmed in four study groups including young and
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aging HIV- individuals and young and aging HIV+ individuals. It is likely that these
genomic and molecular variations in IgM memory B cells play an important role in
regulating B cell activation and function in response to pneumococcal antigen. Therefore,
further understanding of functionality of these distinct subpopulations and plasticity among
them and complex interplay with other cell types is necessary to better understand their
functional significance and role in immune responses to pneumococcal vaccinations. We
also identified, on a single cell level, that there is a significant reduction in expression of
AICDA in aging HIV+ seen in both pre-immunization and post-immunization IgM
memory B cells and is speculated to be a contributing factor to impaired pneumococcal
vaccine responses. Together these findings significantly increase our understanding of IgM
memory B cell biology that may have future translational implications in design of new
pneumococcal vaccine formulations.
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Chapter 6
Summary of Findings and Future Directions
The focus of HIV research for the past several decades has been on the development
of drugs that can block HIV virus from replicating and as a result prevent the disease
progression, restore the immune system and prolong life. HIV targets have been
successfully identified and a number of effective antiretroviral drugs have been
developed.1,2,3,4 The introduction of these antiretroviral drugs has to led to the ability to
control HIV and resulted in the significant increase in longevity of HIV+ individuals and
a rapid growth of aging HIV+ population. It has been estimated, that in 2015 approximately
47% of Americans living with HIV were aged 50 or older.5 The increasing lifespan of
HIV+ persons represents new challenges combining the immune deficiencies of HIV with
those of aging. HIV infection causes profound changes in the immune responses due to
continuous exposure to new antigens produced by mutations of the virus leading to chronic
inflammation. Recent studies have shown that these changes closely resemble
immunological changes in uninfected individuals that are decades older.6,7,8 Both the aging
process and HIV infection are characterized by chronic inflammation and
hypercoagulability and result in high susceptibility to various infections.6,9
Streptococcus pneumoniae is a major cause of morbidity and mortality in
individuals infected with human immunodeficiency virus (HIV+).10 An increased
incidence of pneumococcal infection is also common among the elderly over the age of
65.11 As a preventative strategy, pneumococcal vaccination is routinely recommended for
HIV+ persons and the elderly. However, pneumococcal polysaccharide vaccine (PPV) is
poorly efficacious, especially in individuals with nadir CD4 count below 200 and certain
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cohorts of aging population.12,13 As previously discussed, this is likely caused by
significant perturbations in B cell immunity caused by HIV-disease and aging that result
in production of antibodies with reduced specificity and affinity leading to poor recall and
novel vaccine antigen responses. 6,9,14,15
The goal of the current study was to assess age-related changes in humoral and
cellular responses to pneumococcal vaccination in aging HIV+ individuals and define
potential mechanisms of impaired immune responses to pneumococcal vaccination in
HIV+ adults.
We evaluated quantitative and qualitative antibody responses to pneumococcal
serotypes 14 and 23F in young and aging HIV+ individuals as compared to age-matched
HIV- individuals. We report a significant increase in serotype-specific (14 and 23F) IgM
and IgG levels in all groups, with the exception of young HIV+ group, that did not
demonstrate an increase in serotype 23F specific IgG antibodies. Although the increase in
antibody production was markedly increased, the results clearly show that immunological
response in both young and aging HIV+ groups was inferior as compared to young HIVgroup. We measured functionality of antibodies produced in response to serotypes 14 and
23F by opsonophagocytic assay. This assay is generally regarded as a better correlate of
protection.

16,17

We found that HIV+ groups demonstrated a significant increase in

functional antibody production against serotypes 14 and 23F, however the immune
response was not as robust as in HIV- young adults.
Collectively, we report that young and aging HIV+ individuals do not follow the
same patterns as young and aging HIV- individuals in terms of production of antibodies
and functional antibodies to pneumococcal antigens. We demonstrated significant
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differences between pneumococcal vaccine responses in young as compared to aging
healthy groups, however there were no differences in functional antibody response in
young HIV+ as compared to aging HIV+ groups. These findings suggest that perhaps HIV
infection rather than age has a more profound impact on immune response to pneumococcal
vaccination in HIV+ adults.
Another factor, which plays a role in pneumococcal vaccine responses is ethnic
background. Several studies have shown that African American race is associated with
increased

incidence

of

invasive

pneumococcal

disease

in

the

HIV-positive

population.18,19,20 It was also shown that 23-valent pneumococcal polysaccharide vaccine
is 76% effective in Caucasians and only 23% effective in black patients with similar CD4
counts.20 Together, these findings led us to evaluation of race-related differences in
functional antibody responses to pneumococcal serotypes 14, 19A, and 23F. We found
significant differences in the OPA titers between African American and Caucasian
populations post-immunization with polysaccharide vaccine PPV23 in the response to 2
out of 3 serotypes tested: 14 and 19A. However, prior immunization with conjugate vaccine
(PCV13) was able to overcome ethnical differences for serotype 19A, but not in response
to serotype 14. Reduced antibody activity was found to be related to distinctions in preimmunization gene expression levels. In agreement we other studies, we showed that
African American HIV+ individuals had significantly higher levels of expression of 33
genes on the single cell level as compared to Caucasian HIV+ person. 21 We concluded that
these differences were important contributing factors to distinctions in immune response
to pneumococcal antigens.
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To elucidate factors that contribute to impaired pneumococcal vaccine responses in
aging HIV+ individuals, we evaluated the relationship between functional antibodies and
inflammatory markers expressed prior to immunization. We found that aging HIV+
individuals have significantly higher levels of expression of IP-10, sCD40L, TNF-α and
APRIL as compared to aging HIV- individuals. Furthermore, there was a significant
correlation between IP-10 expression and functional antibody response to serotype 23F but
not to serotype 14 in aging HIV+ persons. IP-10 has been reported to play a role in plasma
cell development including class switching, proliferation, and terminal differentiation
through a STAT3 dependent mechanism. It is speculated that there is a dysregulation of
STAT3 signaling as a result of elevated levels of IP-10, which could potentially have an
adverse effect on functional antibody production in response to pneumococcal antigens.
However, future studies are required to better understand this relationship.22,23,24
To further probe mechanisms of suboptimal pneumococcal vaccine responses in
aging HIV+, we performed in depth phenotypic characterization of pre-immunization and
post-immunization polysaccharide specific IgM memory B cells, a key regulator of
responses to pneumococcal antigens. We utilized the methods of flow cytometry and single
cell RT PCR.
We found that the phenotype of PPS-specific IgM memory B cells changes with
age in healthy individuals from IgM memory in HIV- young adults to switched memory B
cells in aging HIV- individuals. However, HIV+ individuals do not undergo a similar
phenotypic shift. Furthermore, the phenotype of PPS-specific B cells is predominantly IgM
memory, which closely resembles the phenotype of HIV- young adults but in significantly
lower levels. Importantly, healthy young adults produce high levels of functionally
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antibodies in response to pneumococcal antigens, however it is not the case in aging HIV+.
It is clear that the absolute number (but not percentage) of IgM memory B cells is
significantly lower in HIV+ young and aging persons as compared to HIV-. However, low
number of IgM memory B cells alone may not explain the significant changes in immune
responses. We postulated that the IgM memory B cells in HIV+ persons were functionally
impaired. To understand, how phenotypically similar cells may behave functionally
different, we evaluated gene expression levels on a single cell level in IgM memory B cells
pre- and post-immunization. We found that both antigen-specific and antigen non-specific
IgM memory B cells are in fact heterogeneous and consist of subpopulations that are
functionality different and were present in young and aging HIV+ and HIV- groups. Single
cell analysis of non-specific IgM memory B cells revealed that subpopulation 1 was more
likely to dominate in T cell independent immune responses as compared to subpopulation
2. It demonstrated increased levels of expression of BAFF-R, TACI, co-stimulatory
molecules such as CD80/CD86 as well as TCF3 that have been previously shown to play
an important role in immune responses to polysaccharide antigens. Furthermore, this
subpopulation showed higher levels of expression of metabolic genes and genes that play
a role in cell communication within study groups. In PPS-specific IgM memory B cells we
observed similar findings. There were two distinct subpopulations of PPS-specific IgM
memory B cells present in all study groups with post-immunization subpopulation 1 being
more activated as shown by expression levels of TACI, BAFF-R as well as CD86 and
CD40. We found that levels of AICDA were significantly lower in aging HIV+ group not
only in post-immunization subpopulation 1 but also in post-immunization subpopulation
2. AICDA was also low in aging HIV- group. AICDA is an important regulator of AID
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which is essential for generation of antibody memory. We speculated that abnormal levels
of AICDA in aging HIV+ individuals could be potentially implicated in B cell dysfunction,
rapid decrease in antibody levels and impaired vaccine responses. Taken together,
advantages of single cell technologies enabled us to detect heterogeneity present within
IgM memory B cell populations which can have a significant impact on ability to produce
immune response to pneumococcal antigens.
We recognize that our study has limitations. First, our sample size was small, which
limits the power of the study, however we were able to observe statistically significant
differences between the study groups. Second, we reported the immune response to
serotypes 14, 19A, and 23F, therefore it remains to be investigated if similar results would
be obtained for other serotypes. Finally, vaccination regimen in young HIV- group was
different from other study groups. These individuals did not receive Prevnar13 prior to
receiving Pneumovax23. Generally, healthy young adults are not required to receive
pneumococcal vaccination because they are not considered to be at high risk of IPD. In this
study, this group was included as a positive control and was used as reference of a robust
immune response and therefore the results for this group must be interpreted with care.
Overall, our study demonstrated that the immune response to pneumococcal
vaccination in aging HIV-positive individuals is complex and shaped by multiple factors
including HIV infection, inflammatory status, and phenotypic characteristics of IgM
memory B cells. Evaluation of antibody production, opsonophagocytic activity and
phenotypes of antigen-specific B cells produced in response to pneumococcal vaccination
in young and aging HIV+ groups revealed unique characteristics that were not observed in
healthy persons. We found a number of similarities between young HIV+ and aging HIV+
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individuals including generally low levels of antigen-specific IgM and IgG antibodies,
highly variable levels of OPA titers and no distinct separation in the phenotype of PPSspecific B cells produced post-immunization. In contrast, young HIV- group displayed
significantly higher levels of IgM and IgG antibodies, OPA titers and predominant IgM
memory B cell phenotype as compared to aging HIV- individuals who had predominantly
switched memory phenotype. We conclude that there are significant age-related changes
in the immune response to pneumococcal vaccination in healthy individuals, and although
young and aging HIV+ adults exhibit comparable responses and appear to not undergo a
similar shift, the aging HIV+ IgM memory B cells demonstrate some distinct aging-related
features such as low expression of AICDA.
To sum up, our study emphasized the need for continued investigation of IgM
memory B cell biology and provides a foundation for future studies. Utilization of new
stimuli to enhance B cell responses to pneumococcal antigens could be the key to a
significant improvement of pneumococcal vaccine formulations that results in better
response rates in high risk populations such as the elderly and HIV+. The specific targets
however, remain to be determined. Towards this goal, our future studies will include
further characterization of IgM memory B cells subpopulations using functional studies
and proteomic analysis in order to define specific functional states and plasticity of these
cells. Furthermore, we will perform in vitro studies to understand the effects of low levels
of AICDA, the major regulator of AID on B cell response to polysaccharide antigens.
Finally, we will investigate whether levels of AICDA can be regulated by inducing TLR
activation via unmethylated CpG oligodeoxynucleotides, an important factor shown to
increase anti-PPS immunoglobulin production and a potential vaccine adjuvant.
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